var title_f33_13_34000="Acromegaly features PI";
var content_f33_13_34000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Facial features of acromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A man with acromegaly showing the characteristic changes of enlargement of the jaw, nose and frontal bones, and coarse facial features.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Verna Wright, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34000=[""].join("\n");
var outline_f33_13_34000=null;
var title_f33_13_34001="Patient information: Muscular dystrophy (The Basics)";
var content_f33_13_34001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15489\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/32/18957\">",
"         Most common forms of muscular dystrophy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/33/32276\">",
"         Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Muscular dystrophy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/muscular-dystrophy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H539154536\">",
"      <span class=\"h1\">",
"       What is muscular dystrophy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Muscular dystrophy is the term doctors use for a group of disorders that all cause muscle weakness. These disorders run in families. Some forms of muscular dystrophy affect only boys. Other forms affect both boys and girls. The symptoms of most forms of muscular dystrophy start in childhood. But some forms start in adulthood.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539154543\">",
"      <span class=\"h1\">",
"       What are the symptoms of muscular dystrophy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of muscular dystrophy differ depending on what type you have. This table lists the most common types of muscular dystrophy and the symptoms they cause (",
"      <a class=\"graphic graphic_table graphicRef61217 \" href=\"mobipreview.htm?18/32/18957\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539154550\">",
"      <span class=\"h1\">",
"       Is there a test for muscular dystrophy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for muscular dystrophy, the doctor might order:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests to check for proteins that get released when muscles are damaged",
"       </li>",
"       <li>",
"        Blood or other kinds of tests to check for the genes that cause muscular dystrophy",
"       </li>",
"       <li>",
"        A test called &ldquo;electromyography,&rdquo; or &ldquo;EMG.&rdquo; For this test, the doctor inserts tiny needles into a muscle and passes a gentle electrical current.",
"       </li>",
"       <li>",
"        A muscle biopsy, which means that the doctor takes a tiny chunk of muscle. That way he or she can look at the muscle cells under a microscope and see if the cells look normal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539154557\">",
"      <span class=\"h1\">",
"       How is muscular dystrophy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often there are no good treatments for muscular dystrophy. But some forms of muscular dystrophy can be treated with medicines called steroids. (These medicines are different than the steroids athletes take to build up muscle. These steroids reduce inflammation.) There are also braces, wheelchairs, and other devices that can help with some of the problems caused by muscular dystrophy.",
"     </p>",
"     <p>",
"      Some forms of muscular dystrophy can cause problems with the heart, lungs, and other organs. For this reason, children who have muscular dystrophy often need to be checked for these problems as they get older. Ask your doctor whether you or your child needs to be checked for any problems over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539154564\">",
"      <span class=\"h1\">",
"       What if I want to have children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you or any of your close relatives has muscular dystrophy, ask your doctor or nurse whether you could pass it on to your children. Women can pass on the disorder even if they have no symptoms.",
"     </p>",
"     <p>",
"      If you or your partner gets pregnant, it might be possible to have tests before the baby is born to find out if the baby has the disorder.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539154571\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with the muscular dystrophy live fairly long lives. But their physical abilities are often limited. Some forms of muscular dystrophy can shorten a person&rsquo;s life. If you or your child has muscular dystrophy, ask your doctor about what to expect.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539154578\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/33/32276?source=see_link\">",
"       Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/13/34001?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15489 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34001=[""].join("\n");
var outline_f33_13_34001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539154536\">",
"      What is muscular dystrophy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539154543\">",
"      What are the symptoms of muscular dystrophy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539154550\">",
"      Is there a test for muscular dystrophy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539154557\">",
"      How is muscular dystrophy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539154564\">",
"      What if I want to have children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539154571\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539154578\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15489\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/32/18957\">",
"      Most common forms of muscular dystrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/33/32276?source=related_link\">",
"      Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_13_34002="Dividing the parametrium";
var content_f33_13_34002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dividing the parametrium during radical hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ureters are retracted as far lateral as possible and the parametrium divided at the sidewall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34002=[""].join("\n");
var outline_f33_13_34002=null;
var title_f33_13_34003="Solar urticaria";
var content_f33_13_34003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Solar urticaria induced by ultraviolet A light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Shoulder before sun exposure.",
"    <br>",
"     (B) Shoulder after 15 minutes of sun exposure through a glass window. The glass window filters out ultraviolet B light.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34003=[""].join("\n");
var outline_f33_13_34003=null;
var title_f33_13_34004="Approach to the infant with hypotonia and weakness";
var content_f33_13_34004=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the infant with hypotonia and weakness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Olaf A Bodamer, MD, FACMG, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Geoffrey Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34004/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/13/34004/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular diseases frequently present in newborns or infants with hypotonia and weakness. However, these signs also occur in many common disorders such as sepsis, organ failure, and metabolic dysfunction. If these latter conditions can be excluded, hypotonia probably is caused by a primary neuromuscular disorder.",
"   </p>",
"   <p>",
"    Assessment of the infant with hypotonia and weakness is reviewed here. The causes of hypotonia and weakness caused by peripheral nerve and muscle diseases (",
"    <a class=\"graphic graphic_table graphicRef66572 \" href=\"mobipreview.htm?27/44/28365\">",
"     table 1",
"    </a>",
"    ) and the evaluation of specific neuromuscular disorders are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11015?source=see_link\">",
"     \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obstetric and perinatal history may provide information that supports the diagnosis of a neuromuscular disorder. Affected infants frequently have a history of polyhydramnios (caused by decreased fetal swallowing), fetal akinesia (paucity of movement), and malpresentation (often in the breech position).",
"   </p>",
"   <p>",
"    Delivery may be complicated by birth trauma or perinatal depression. Although these complications can occur in normal infants, infants with congenital neuromuscular disorders may be less able to tolerate the stress associated with labor and delivery and, thus, be more susceptible to birth depression.",
"   </p>",
"   <p>",
"    A family history of neuromuscular abnormalities may be informative because many disorders are inherited. Examples of familial neuromuscular diseases are congenital myotonic dystrophy, spinal muscular atrophy, metabolic disorders (eg, mitochondrial disease, acid maltase deficiency, defects of creatine synthesis), and familial dysautonomia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination begins with an assessment of the infant's general health. Dysmorphic features and congenital defects should be identified. Weight, length, and head circumference should be measured and the data obtained plotted against standard measurements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=see_link&amp;anchor=H7#H7\">",
"     \"The pediatric physical examination: General principles and standard measurements\", section on 'Standard measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain physical findings may be helpful in making the diagnosis of a specific neuromuscular disorder. These findings, and examples of specific conditions, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin pallor, bruising, petechiae, or evidence of trauma (eg, traumatic myelopathy) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11015?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\", section on 'Traumatic myelopathy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abnormalities of respiratory rate, pattern, or diaphragmatic movement (eg, congenital myopathies)",
"     </li>",
"     <li>",
"      Cardiomyopathy (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency, fatty acid oxidation disorders)",
"     </li>",
"     <li>",
"      Organomegaly (eg, acid maltase deficiency)",
"     </li>",
"     <li>",
"      Defects of the genitalia, including hypogonadism (eg, Smith-Lemli-Opitz syndrome) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link\">",
"       \"Evaluation of the infant with ambiguous genitalia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Contractures or laxity of the hips or other joints (eg, Ehlers-Danlos syndrome, arthrogryposis multiplex congenita) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11015?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\", section on 'Arthrogryposis multiplex congenita'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEUROLOGIC EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete neurologic examination should be performed with particular attention given to the extent of hypotonia and weakness and the possible presence of other findings that may indicate a specific disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34004/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14505?source=see_link\">",
"     \"Neurological examination of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment should include the infant's posture and level of alertness. Spontaneous activity should be observed, noting whether limb movement is greater proximally or distally and opposes gravity (eg, lifting an extremity).",
"   </p>",
"   <p>",
"    Eye movements are assessed as part of the cranial nerve examination. Spontaneous movements, such as fixation on objects and following them, can be observed in response to the examiner's face or a red ball. Eye movements also can be induced by gentle rotation of the head (oculocephalogyric reflex). Absent fixation or following with a positive oculocephalogyric reflex suggests a lesion above the level of the brainstem.",
"   </p>",
"   <p>",
"    Facial diplegia occurs in some neuromuscular disorders (eg, congenital myotonic dystrophy). It also can be associated with severe acute basal ganglia damage (eg, mitochondrial disease, Leigh disease). The infant's ability to suck and swallow should be assessed; difficulty with swallowing may lead to pooling of secretions.",
"   </p>",
"   <p>",
"    The character of the cry should be noted, and the tongue should be examined for fasciculations, which typically are associated with spinal muscular atrophy. However, they also are seen with hypoglossal motor nerve damage that occurs in conditions including glycogen storage diseases, hypoxic-ischemic injury, and infantile neuronal degeneration.",
"   </p>",
"   <p>",
"    The degree of hypotonia should be evaluated. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Assessment of muscle tone'",
"    </a>",
"    below.) Passive movement of the joints is done to test the power and tone of the extremities. Tone also is evaluated by the resistance to gentle shaking of an arm or leg (eg, passive response). Spontaneous fisting or an abnormal primitive reflex in response to handling may suggest cerebral dysfunction.",
"   </p>",
"   <p>",
"    Deep tendon reflexes may help distinguish between upper and lower motor neuron lesions. Abnormally brisk reflexes with clonus suggest involvement of the upper tract, whereas absent reflexes are consistent with a neuropathic lesion or severe myopathy. Primary neonatal reflexes, including the Moro reflex, tonic neck response, palmar grasp, and placing and stepping reactions, should be evaluated.",
"   </p>",
"   <p>",
"    Sensation should be tested by the withdrawal to a stimulus such as touching the patient with a small brush. Abnormalities in sensation associated with neonatal hypotonia can result from conditions such as hereditary sensory neuropathy (eg, familial dysautonomia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34004/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF MUSCLE TONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of muscle tone is performed as part of the complete physical examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34280?source=see_link&amp;anchor=H7#H7\">",
"     \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\", section on 'Neurologic examination'",
"    </a>",
"    .) The patient with hypotonia is distinguished readily from an infant with normal muscle tone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Normal muscle tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal term infant, both the upper and lower limbs have predominantly flexor tone. Normal posture in the supine position includes flexion of the hips at approximately 70&ordm; to 90&ordm; and abduction at 10&ordm; to 20&ordm;, and the child has active movement of the limbs. Maneuvers to test muscle tone and normal responses include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Holding the infant under the arms &ndash;",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      will assume a sitting position; truncal resistance allows the infant to be easily supported without slipping through the examiner's hands",
"     </li>",
"     <li>",
"      Holding the infant in horizontal suspension &ndash;",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      flexes the limbs, straightens the back, and maintains the head in the midline for a few seconds.",
"     </li>",
"     <li>",
"      Passive extension of the legs at the knees &ndash; resistance is met at approximately 90&ordm;.",
"     </li>",
"     <li>",
"      Pulling the infant from the supine to sitting position &ndash; only a slight head lag is expected; the head should wobble in the midline for a few seconds when the sitting position is reached.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal muscle tone is decreased in premature compared to term infants. Flexor tone in premature infants diminishes with decreasing gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34004/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22068?source=see_link\">",
"     \"Postnatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypotonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypotonic infant lies supine in a frog-like position with the hips abducted and the limbs abnormally extended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34004/abstract/6\">",
"     6",
"    </a>",
"    ]. Spontaneous activity is decreased. The resistance of muscles to stretch is decreased, as illustrated by the following movements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Holding the infant under the arms &ndash; the legs will be extended; decreased tone of the shoulder girdle allows the infant to slip through the examiner's hands.",
"     </li>",
"     <li>",
"      Holding the infant in horizontal suspension &ndash; the back hangs over the examiner's hand, and the limbs and head hang loosely.",
"     </li>",
"     <li>",
"      Passive extension of the legs at the knees &ndash; no resistance is met.",
"     </li>",
"     <li>",
"      Pulling the infant from the supine to sitting position &ndash; the head lags and continues to lag when the sitting position is reached.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These maneuvers should not be performed when cervical spine injury is present or the infant is in severe distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Distinguishing among disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative changes in tone, muscle strength, and antigravity activity may help distinguish among neuromuscular disorders (",
"    <a class=\"graphic graphic_table graphicRef66572 \" href=\"mobipreview.htm?27/44/28365\">",
"     table 1",
"    </a>",
"    ). In general, in a central nervous system disorder (eg, Leigh syndrome), tone is reduced relatively more than muscle strength, and the limbs retain antigravity power [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34004/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, absent, or extremely reduced antigravity movements can be reliable indicators of a neuromuscular disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34004/abstract/7\">",
"     7",
"    </a>",
"    ]. However, numerous exceptions occur as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some disorders that are primarily central may present with both profound hypotonia and weakness. They include Prader-Willi syndrome and acute conditions such as hemorrhage or infarction of the deep central gray matter of the brain or spinal cord. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormalities in both the central and peripheral nervous systems can present with hypotonia. Examples include congenital muscular dystrophy, congenital myotonic dystrophy, cervical spinal cord injury, acid maltase deficiency, and some mitochondrial and peroxisomal disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/14/41192?source=see_link&amp;anchor=H16#H16\">",
"       \"Oculopharyngeal, distal, and congenital muscular dystrophies\", section on 'Congenital muscular dystrophies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8570?source=see_link\">",
"       \"Peroxisomal disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11015?source=see_link\">",
"       \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants with a mild congenital myopathy can retain antigravity power in the limbs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13417?source=see_link\">",
"       \"Congenital myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Conditions such as Ehlers-Danlos syndrome or osteogenesis imperfecta can present with hypotonia. In these disorders, hypotonia results from ligamentous laxity, rather than an acute metabolic or systemic illness or a neurologic abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of disorders may present in infants as hypotonia and weakness, including neuromuscular diseases, central nervous system disorders, sepsis, organ failure, and metabolic dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with neuromuscular disorder frequently have a history of polyhydramnios, fetal akinesia, and malpresentation. A family history of neuromuscular abnormalities may be present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical findings that may be helpful in making the diagnosis of a specific neuromuscular disorder include dysmorphic features, bruising or petechiae, respiratory abnormalities, cardiomyopathy, organomegaly, defects of the genitalia (including hypogonadism), and joint contractures or laxity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough neurological examination should be performed, including assessment of the degree of hypotonia and weakness, evidence of cranial nerve dysfunction (facial diplegia, eye movements, suck and cry), deep tendon and neonatal reflexes, and sensation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neurologic examination'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14505?source=see_link\">",
"       \"Neurological examination of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypotonia in an infant is characterized by a frog-like position when supine, with decreased spontaneous activity, and decreased muscle resistance to stretch. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypotonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, in a central nervous system disorder, tone is reduced relatively more than muscle strength, and the limbs retain antigravity power. In contrast, neuromuscular disorders are more likely to exhibit profound weakness, manifested by inability to move the limbs against gravity. However, numerous exceptions occur. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Distinguishing among disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Volpe JJ. Neurological examination: Normal and abnormal features. In: Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34004/abstract/2\">",
"      Axelrod FB, Porges RF, Sein ME. Neonatal recognition of familial dysautonomia. J Pediatr 1987; 110:946.",
"     </a>",
"    </li>",
"    <li>",
"     Amiel-Tison C, Grenier A. Neurological Assessment During the First Year of Life, Oxford University Press, New York 1986.",
"    </li>",
"    <li>",
"     Dubowitz LM, Dubowitz V. The Neurological Assessment of the Preterm and Fullterm Infant, JB Lippincott Co, Philadelphia 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34004/abstract/5\">",
"      Amiel-Tison C, Maillard F, Lebrun F, et al. Neurological and physical maturation in normal growth singletons from 37 to 41 weeks' gestation. Early Hum Dev 1999; 54:145.",
"     </a>",
"    </li>",
"    <li>",
"     Dubowitz V. The Floppy Infant, JB Lippincott Co, Philadelphia 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34004/abstract/7\">",
"      Vasta I, Kinali M, Messina S, et al. Can clinical signs identify newborns with neuromuscular disorders? J Pediatr 2005; 146:73.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6148 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34004=[""].join("\n");
var outline_f33_13_34004=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEUROLOGIC EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASSESSMENT OF MUSCLE TONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Normal muscle tone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypotonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Distinguishing among disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6148\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6148|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/44/28365\" title=\"table 1\">",
"      Newborn neuromuscular disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13417?source=related_link\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14505?source=related_link\">",
"      Neurological examination of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11015?source=related_link\">",
"      Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22068?source=related_link\">",
"      Postnatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_13_34005="Diagnostic approach to hypocalcemia";
var content_f33_13_34005=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to hypocalcemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34005/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34005/contributors\">",
"     David Goltzman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34005/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34005/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34005/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34005/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/13/34005/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia has many causes (",
"    <a class=\"graphic graphic_table graphicRef62899 \" href=\"mobipreview.htm?3/62/4077\">",
"     table 1",
"    </a>",
"    ). It can result from inadequate parathyroid hormone (PTH) secretion, parathyroid hormone resistance, vitamin D deficiency or resistance, abnormal magnesium metabolism, and extravascular deposition of calcium, which can occur in several clinical situations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=see_link\">",
"     \"Etiology of hypocalcemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=see_link\">",
"     \"Etiology of hypocalcemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approach to hypocalcemia involves confirming, by repeat measurement, the presence of hypocalcemia and distinguishing among the potential etiologies. The diagnosis may be obvious from the patient's history; examples include chronic kidney disease and postsurgical hypoparathyroidism. When the cause is not obvious or a suspected cause needs to be confirmed, other biochemical tests are indicated.",
"   </p>",
"   <p>",
"    This topic will review the evaluation of patients with hypocalcemia. The clinical manifestations and treatment of hypocalcemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF SERUM CALCIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation of a patient with hypocalcemia is measurement of the serum albumin concentration. Calcium in serum is bound to proteins, principally albumin. As a result, the total serum calcium concentration in patients with low or high serum albumin levels may not accurately reflect the physiologically important ionized (or free) calcium concentration. Each 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    reduction in the serum albumin concentration will lower the total calcium concentration by approximately 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    without affecting the ionized calcium concentration and therefore without producing any symptoms or signs of hypocalcemia.",
"   </p>",
"   <p>",
"    A patient who has a serum albumin concentration of 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    which is 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    below normal, will have a fall in serum total calcium concentration of 1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.4",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    If the measured serum total calcium concentration is 8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    then the corrected value will be 9.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    which is normal. Thus, in patients with hypoalbuminemia or hyperalbuminemia, the measured serum calcium concentration should be corrected for the abnormality in serum albumin (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?17/35/17969?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for standard units (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/51/15153?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the diagnosis of hypocalcemia is in doubt, either because the patient's symptoms are atypical or the patient's serum calcium concentration is only slightly low, serum ionized calcium should be measured if a laboratory known to measure ionized calcium reliably is available. It is important to note that the affinity of calcium for albumin is increased in the presence of alkalosis. Thus, respiratory alkalosis may cause an acute decrease in ionized calcium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23685?source=see_link\">",
"     \"Relation between total and ionized serum calcium concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, it is important to verify with repeat measurement (ionized calcium or total serum calcium corrected for albumin) that there is a true decrease in the serum calcium concentration. If available, previous values for serum calcium should also be reviewed. If the patient has a low albumin-corrected serum calcium or ionized calcium concentration, further evaluation to identify the cause is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of hypocalcemia may be obvious from the clinical history. A family history of hypocalcemia suggests a genetic cause. Chronic hypocalcemia is often seen in patients with an activating mutation of the calcium sensing receptor and in pseudohypoparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology of hypocalcemia in infants and children\", section on 'End-organ resistance/pseudohypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, acquired hypoparathyroidism is most often the result of postsurgical or autoimmune damage to the parathyroid glands. Postsurgical hypoparathyroidism can occur after thyroid, parathyroid, or radical neck surgery for head and neck cancer. Thus, a history of head and neck surgery or the presence of a neck scar suggests postsurgical hypoparathyroidism.",
"   </p>",
"   <p>",
"    Autoimmune hypoparathyroidism can occur as an isolated abnormality and is also a common feature of polyglandular autoimmune syndrome type I, which is a familial disorder. The presence of chronic mucocutaneous candidiasis and adrenal insufficiency suggests a polyglandular syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type I'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of hypocalcemia that may be apparent from the history, physical examination, and routine laboratory data include acute or chronic kidney disease, acute pancreatitis, rhabdomyolysis, and marked increases in tissue breakdown with the release of phosphate from cells, as occurs in the tumor lysis syndrome (",
"    <a class=\"graphic graphic_table graphicRef62899 \" href=\"mobipreview.htm?3/62/4077\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=see_link\">",
"     \"Etiology of hypocalcemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination may reveal findings of latent tetany, such as Chvostek's and Trousseau's signs, which are strongly suggestive of hypocalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the tests that may be helpful in defining the etiology of hypocalcemia, measurement of serum intact parathyroid hormone is the most valuable and should be performed in all patients with hypocalcemia (",
"    <a class=\"graphic graphic_table graphicRef72080 \" href=\"mobipreview.htm?18/31/18940\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34005/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Serum PTH concentrations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other measurements that may be helpful include serum magnesium, creatinine, phosphate, the vitamin D metabolites calcidiol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D, the active vitamin D hormone), alkaline phosphatase, amylase, and urinary calcium and magnesium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34005/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These tests should be performed selectively, based upon the patient's history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serum PTH concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum intact PTH measurements provide critical information in patients with hypocalcemia, but can be interpreted correctly only when serum calcium is measured simultaneously (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"mobipreview.htm?33/8/33935\">",
"     figure 1",
"    </a>",
"    ). Hypocalcemia is the most potent stimulus of PTH secretion; as a result, a low or even normal serum PTH concentration in a patient with hypocalcemia is strong evidence of hypoparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum PTH concentration varies with the cause of the hypocalcemia (",
"    <a class=\"graphic graphic_table graphicRef62899 \" href=\"mobipreview.htm?3/62/4077\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72080 \" href=\"mobipreview.htm?18/31/18940\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum PTH is reduced or inappropriately normal in patients with hypoparathyroidism.",
"     </li>",
"     <li>",
"      Serum PTH is elevated in patients with acute or chronic kidney disease, vitamin D deficiency, and pseudohypoparathyroidism.",
"     </li>",
"     <li>",
"      Serum PTH is typically normal or low in patients with hypomagnesemia or autosomal dominant hypocalcemia, a rare disorder characterized by an activating mutation in the calcium-sensing receptor gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia (serum magnesium concentration below 0.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 0.4",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    causes hypocalcemia by inducing PTH resistance or deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum magnesium should be measured in any patient with hypocalcemia in whom the cause is not obvious. Hypocalcemia should resolve within minutes or hours after restoration of normal serum magnesium concentrations if hypomagnesemia was the cause of the hypocalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of hypocalcemia\", section on 'Concurrent hypomagnesemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few patients with magnesium-responsive hypocalcemia have",
"    <strong>",
"     normal",
"    </strong>",
"    serum magnesium concentrations. These patients are presumed to have tissue magnesium deficiency. Thus, magnesium supplementation may be indicated in patients with unexplained hypocalcemia who are at risk for hypomagnesemia, such as patients with chronic malabsorption or alcoholism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link&amp;anchor=H8#H8\">",
"     \"Signs and symptoms of magnesium depletion\", section on 'Normomagnesemic magnesium depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent hypocalcemia and hyperphosphatemia is, in the absence of kidney disease or increased tissue breakdown, virtually diagnostic of either hypoparathyroidism (PTH deficiency) or pseudohypoparathyroidism (PTH resistance). The elevated serum phosphate concentration in patients with either disorder is due to loss of the stimulatory effect of PTH on urinary phosphate excretion and is therefore associated with an inappropriately low fractional excretion of phosphate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=see_link\">",
"     \"Diagnosis and treatment of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a low serum phosphate concentration indicates either excess PTH secretion, which in the context of hypocalcemia means secondary hyperparathyroidism (and some abnormality in vitamin D intake or metabolism), or low dietary phosphate intake, which is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vitamin D metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency increases PTH secretion by causing hypocalcemia (due to the reduction in intestinal calcium absorption) and, to a lesser degree, by removing the normal inhibitory effect of calcitriol on PTH production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34005/abstract/5\">",
"     5",
"    </a>",
"    ]. Vitamin D deficiency also diminishes intestinal phosphate absorption. Excess PTH enhances phosphate excretion and lowers the serum phosphate.",
"   </p>",
"   <p>",
"    Measurement of serum 25-hydroxyvitamin D (25OHD, calcidiol) provides more information about vitamin D deficiency than does measurement of serum 1,25-dihydroxyvitamin D (calcitriol) because the hypocalcemia-induced increase in PTH secretion stimulates renal 1,25-dihydroxyvitamin D production (in patients without underlying renal insufficiency). Thus, in individuals with vitamin D deficiency, serum 25OHD is low whereas 1,25-dihydroxyvitamin D is typically normal or high. In contrast, patients with hypoparathyroidism may have normal serum 25OHD and low 1,25-dihydroxyvitamin D concentrations (",
"    <a class=\"graphic graphic_table graphicRef72080 \" href=\"mobipreview.htm?18/31/18940\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The various causes of vitamin D deficiency usually can be distinguished by the history and other clinical findings (deficient dietary intake, inadequate sunlight exposure, malabsorption,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    therapy) and by measurement of serum 25-hydroxyvitamin D (25OHD, calcidiol). A more in-depth discussion of the individual disorders can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following patterns in vitamin D metabolites and serum phosphate may be seen in patients with hypocalcemia and secondary increases in PTH and point to different underlying causes of hypocalcemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low serum 25OHD concentration in a patient with hypocalcemia and hypophosphatemia usually indicates that vitamin D intake or absorption (usually coupled with decreased production in skin) is low (",
"      <a class=\"graphic graphic_table graphicRef72080 \" href=\"mobipreview.htm?18/31/18940\">",
"       table 2",
"      </a>",
"      ). Other possibilities include phenytoin therapy, hepatobiliary disease, or the nephrotic syndrome (in which vitamin D-binding protein is lost in the urine).",
"     </li>",
"     <li>",
"      The combination of normal or low serum 25OHD concentration and low serum 1,25-dihydroxyvitamin D concentration, with high-normal or elevated serum phosphate, indicates the presence of chronic kidney disease (easily diagnosed from the serum creatinine concentration). Chronic kidney disease is the only condition in which hypocalcemia and secondary hyperparathyroidism are not associated with low or low-normal serum phosphate (as a result of the inability of the diseased kidney to respond to the high PTH).",
"     </li>",
"     <li>",
"      The combination of normal or low serum 25OHD concentration, low serum 1,25-dihydroxyvitamin D concentration, and low serum phosphate suggests the presence of vitamin D-dependent rickets, type 1 (renal 1-alpha-hydroxylase deficiency), also called pseudo-vitamin D deficient rickets. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link&amp;anchor=H12#H12\">",
"       \"Etiology and treatment of calcipenic rickets in children\", section on 'Vitamin D dependent rickets type I'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary vitamin D-resistant rickets (also called vitamin D-dependent rickets, type 2) presents in early childhood and is associated with a defect in the vitamin D receptor. It should be suspected in hypocalcemic patients if serum phosphate is low and serum 1,25-dihydroxyvitamin D concentrations are high. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology and treatment of calcipenic rickets in children\", section on 'Hereditary vitamin D resistant rickets'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that may be helpful in determining the cause of hypocalcemia include serum alkaline phosphatase, serum amylase, and 24-hour urinary excretion of calcium and magnesium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevated alkaline phosphatase is common in osteomalacia (as a result of severe vitamin D deficiency and secondary hyperparathyroidism) and can occur with osteoblastic bone metastases, which can cause hypocalcemia due to rapid deposition of calcium in bone metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34005/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum amylase is elevated in acute pancreatitis but only slightly in chronic pancreatitis.",
"     </li>",
"     <li>",
"      Low urinary calcium occurs in patients with untreated hypoparathyroidism or vitamin D deficiency.",
"     </li>",
"     <li>",
"      Assessment of urinary magnesium may be helpful in individuals with hypomagnesemia. In this setting, an elevated value is consistent with renal losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/18/6434?source=see_link\">",
"       \"Patient information: Hypoparathyroidism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypocalcemia has many causes (",
"      <a class=\"graphic graphic_table graphicRef62899 \" href=\"mobipreview.htm?3/62/4077\">",
"       table 1",
"      </a>",
"      ). The diagnostic approach to hypocalcemia involves confirming, by repeat measurement, the presence of hypocalcemia and distinguishing among the potential etiologies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interpretation of serum calcium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of hypocalcemia may be apparent from history and physical examination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the tests that may be helpful in distinguishing the etiology of hypocalcemia, measurement of serum intact parathyroid hormone is the most valuable (",
"      <a class=\"graphic graphic_table graphicRef72080 \" href=\"mobipreview.htm?18/31/18940\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other measurements that may be helpful include serum magnesium, creatinine, phosphate, vitamin D metabolites (primarily 25-hydroxyvitamin D), and alkaline phosphatase. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34005/abstract/1\">",
"      Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008; 336:1298.",
"     </a>",
"    </li>",
"    <li>",
"     Shoback D. Hypocalcemia: Definition, etiology, pathogenesis, diagnosis, and management. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th, Rosen CJ.  (Ed), American Society for Bone and Mineral Research, Hoboken, NJ 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34005/abstract/3\">",
"      Kelly A, Levine MA. Hypocalcemia in the Critically Ill patient. J Intensive Care Med 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34005/abstract/4\">",
"      Khan MI, Waguespack SG, Hu MI. Medical management of postsurgical hypoparathyroidism. Endocr Pract 2011; 17 Suppl 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34005/abstract/5\">",
"      Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011; 15:797.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 837 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34005=[""].join("\n");
var outline_f33_13_34005=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERPRETATION OF SERUM CALCIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serum PTH concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vitamin D metabolites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/837|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/8/33935\" title=\"figure 1\">",
"      PTH and calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/62/4077\" title=\"table 1\">",
"      Major causes hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/31/18940\" title=\"table 2\">",
"      Lab eval hypocalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?17/35/17969?source=related_link\" title=\"calculator 1\">",
"      Calculator: Calcium correction in hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/51/15153?source=related_link\" title=\"calculator 2\">",
"      Calculator: Calcium correction in hypoalbuminemia (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/18/6434?source=related_link\">",
"      Patient information: Hypoparathyroidism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23685?source=related_link\">",
"      Relation between total and ionized serum calcium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_13_34006="PAS positive macrophage";
var content_f33_13_34006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    PAS positive macrophages on microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PAS-positive macrophages in the small intestine of an untreated patient with Whipple's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schneider T, Zeitz M. [Illness and immune manifestations in Whipple disease. Differential rheumatic diseases diagnosis] Internist (Berl) 2003; 44:184. Copyright &copy; 2003 Springer-Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34006=[""].join("\n");
var outline_f33_13_34006=null;
var title_f33_13_34007="Cutaneous melanoma: Management of local recurrence";
var content_f33_13_34007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cutaneous melanoma: Management of local recurrence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Douglas Tyler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34007/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/13/34007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is an aggressive neoplasm that can spread in an unpredictable manner to involve virtually any organ of the body, in contrast to other skin cancers. Early diagnosis and treatment are essential to minimize morbidity and mortality. For patients with cutaneous melanoma, the prognosis is determined by the location and depth of the primary tumor, and the presence or absence of locoregional and distant metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery represents the only potentially curative modality for primary cutaneous melanoma, and adequate excision is important to lessen the risk of a local recurrence. Even if a local recurrence after initial surgery can be successfully managed, these patients often die from subsequent metastatic disease. This observation suggests that local recurrence is a manifestation of aggressive tumor biology and a propensity to develop systemic metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local recurrence has been defined as regrowth within 2 cm of the surgical scar following definitive excision of a primary melanoma with appropriate surgical margins in order to standardize treatment endpoints in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/1\">",
"     1",
"    </a>",
"    ]. This definition does not account for the different mechanisms by which a local recurrence can develop. Furthermore, the 2 cm criterion is based upon distance from the edge of the surgical scar rather than the distance from the original primary tumor, and thus does not take into account the width of the original surgical margins.",
"   </p>",
"   <p>",
"    The management of locally recurrent melanoma will be discussed here. The management of in transit and satellite metastases and the role of surgery in the treatment of metastatic melanoma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link\">",
"     \"Cutaneous melanoma: Management of in transit metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2183?source=see_link\">",
"     \"Surgical management of metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF LOCAL RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A melanoma local recurrence may arise as a result of different mechanisms of disease progression. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incomplete excision of the primary &mdash; A local recurrence may represent retained primary melanoma cells due to incomplete excision of the primary tumor, even in the absence of a \"positive surgical margin\" in the resection specimen. Sampling error prevents a completely accurate histologic analysis of all margins of the excision specimen. At least in theory, a wider excision of the primary melanoma with more generous margins could have prevented this form of local recurrence. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H28#H28\">",
"       \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Cutaneous melanoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In transit metastases &mdash; Another source of melanoma regrowth in close proximity to the original primary tumor is microsatellite or \"in transit\" melanoma nodules that are not excised with the primary tumor mass because they are physically discontinuous from it. The presumed mechanism, lymphatic spread, is supported by the observation that the presence of satellite metastases in a primary excision specimen increases the risk for a subsequent local recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link\">",
"       \"Cutaneous melanoma: Management of in transit metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Second primary melanomas &mdash; Misclassification of a new (de novo) primary melanoma that arises at the periphery of a previously excised melanoma may also be confused with a local recurrence. Histologic evidence of melanoma in situ within a suspected local recurrence should suggest the correct diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link\">",
"       \"Pathologic characteristics of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematologenous dissemination &mdash; A local recurrence can result from hematogenous dissemination with implantation of tumor cells close to the original excision site. A close association between hematogenous dissemination and local recurrence is suggested by data showing a high rate of distant metastases as the next site of relapse in patients with a local melanoma recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This was illustrated by results from 742 patients in the Intergroup Melanoma Trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Among the 28 patients (4 percent) who developed a local recurrence, the next site of relapse was distant and regional in 62 and 28 percent, respectively. If local recurrences were secondary to microsatellites or retained primary tumor cells, regional recurrences would be expected to predominate as the next site of relapse. Moreover, local recurrences were associated with a higher rate of metastases in skin and subcutaneous tissues than in other site, supporting the view that local recurrence reflects hematogenous dissemination to skin or subcutaneous metastases in the vicinity of the primary tumor scar in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR LOCAL RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of local recurrence as a first event in disease progression is estimated to be 3 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The majority occur within five years of initial surgery. Several risk factors for local recurrence have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Width of resection margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A greater risk for local recurrence in patients is associated with thicker primary melanomas. However, excessive sacrifice of normal tissue can affect both function and cosmesis, while inadequate margins can lead to local recurrences that are associated with significant morbidity and mortality. As a result, significant attention has been focused on the width of grossly normal tissue surrounding the primary melanoma (ie, the excision margin) that is necessary to achieve local control.",
"   </p>",
"   <p>",
"    Recommendations for margin width vary according to tumor thickness and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Wide local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anatomic site and ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas arising in the head and neck region and melanomas with ulceration of the primary tumor are at high risk of local recurrence. This was illustrated by results from the Intergroup Melanoma Trial, in which the incidence of local recurrence for primary lesions of the proximal extremities, trunk, distal extremities, and head and neck area were 1.1, 3.1, 5.3, and 9.4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/4\">",
"     4",
"    </a>",
"    ]. Among those with melanomas at low-risk sites (ie, proximal extremities or trunk), the risk of local recurrence was significantly increased if ulceration was present (6.6 versus 1.1 percent without ulceration). Those with primary lesions in high-risk locations (head and neck or distal extremities) also had a significantly increased risk of local recurrence if ulceration was present (16.2 versus 2.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other factors are associated with an increased risk of local recurrence in patients with melanoma. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desmoplastic histology &mdash; Desmoplastic melanomas have been associated with substantially higher rates of local recurrence rate that other cutaneous melanomas. For this reason, adjuvant radiation therapy is often considered following initial resection of these unusual melanomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H15#H15\">",
"       \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Desmoplastic melanoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=see_link&amp;anchor=H7#H7\">",
"       \"Role of radiation therapy in the management of melanoma\", section on 'Adjuvant RT of the primary site'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Node positive disease &mdash; Patients who have node-positive disease, especially those with multiple positive bulky nodes and extracapsular extension, are at an increased risk of local recurrence as well as in the regional nodal basin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=see_link&amp;anchor=H9#H9\">",
"       \"Role of radiation therapy in the management of melanoma\", section on 'Regionally metastatic melanoma: irradiation of high-risk nodal basins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Satellitosis &mdash; The presence of satellite lesions increases the risk of melanoma recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/2-4,6\">",
"       2-4,6",
"      </a>",
"      ]. As an example, in the Intergroup Melanoma Trial there was a significantly higher rate of local recurrence in patients with satellite lesions (32 versus 2 percent in those without satellite lesions) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Timing of local recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of local recurrences are early, but delayed recurrences are not infrequent and more common with thinner lesions (",
"    <a class=\"graphic graphic_table graphicRef57991 \" href=\"mobipreview.htm?29/4/29771\">",
"     table 1",
"    </a>",
"    ). As an example, in the Intergroup Melanoma Trial six of nine patients with melanomas 1 to 2 mm thick recurred five or more years after their initial surgery, while six of eight local recurrences developed within four years in patients with melanomas &ge;2 mm thick.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LOCAL RECURRENCE AND SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of a melanoma local recurrence portends a poor prognosis. In the Intergroup Melanoma Trial, the five-year survival rate was only 9 percent when local recurrence was the first site of failure. The 10-year survival among all patients who recurred locally was only 5 percent. In contrast, there was an 86 percent five-year survival for those patients who did not develop a local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a strong association between local recurrence of melanoma and the prognostic factors known to adversely affect survival. Whether distant metastases result from local or regional recurrences rather than as a manifestation of aggressive tumor biology is not known, but the available data suggest that it is unlikely that a local recurrence itself is responsible for seeding distant metastases. However, local recurrences may seed distant metastases in a subset of patients, and all reasonable measures should be taken to avoid a local recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At one time, the use of a skin graft to cover the melanoma excision site was advocated to allow early detection of a local recurrence with the goal of improving survival. However, the results of the Intergroup Melanoma Trial have dispelled this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. First, the low incidence of local recurrence reduces the value of this strategy, which is associated with significant cost and morbidity. Second, virtually every patient with a local recurrence ultimately died, regardless of whether closure was achieved by a skin graft or not. In multivariate analysis of this trial, closure by skin graft versus primary closure with full-thickness flap had no impact on survival rates, even after accounting for all other factors that influenced the risk of a local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the outlook for most patients with a local recurrence of melanoma is poor, one unusual form of \"true local recurrence\" may be an exception. A local recurrence that is contiguous with the scar and which bears an in situ component that can be excised with a 1 to 2 cm margin is associated with five-year survival rates as high as 89 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/7\">",
"     7",
"    </a>",
"    ]. These lesions have been termed \"true local cutaneous recurrent melanoma\". Many of these lesions probably represent new primary melanomas occurring within a \"field defect\" (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanisms of local recurrence'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a local recurrence of melanoma should undergo a careful evaluation for other sites of recurrence, including a careful history and physical examination and appropriate imaging studies.",
"   </p>",
"   <p>",
"    The evaluation of patients with locoregional recurrence of melanoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35065?source=see_link&amp;anchor=H5#H5\">",
"     \"Staging work-up and surveillance after treatment of melanoma\", section on 'Clinical stage III and local recurrence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15450?source=see_link\">",
"     \"Imaging studies in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for most melanoma local recurrences. For patients who are examined at regular intervals following the treatment of a primary melanoma, local recurrences are more likely to be detected at a stage in which they can be successfully managed by surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35065?source=see_link\">",
"     \"Staging work-up and surveillance after treatment of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most melanoma surgeons recommend the use of resection margins for recurrences that are sufficient to ensure a grossly and microscopically clear margin, although there are no data that definitively address this issue. Radical surgery employing extensive margins for a local recurrence is not justified. However, even when more conservative margins are used to excise a local recurrence, the surgical defect often requires use of a skin graft, because of the previous wide local excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Lymphatic mapping and SLN biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic mapping and sentinel lymph node (SLN) biopsy in patients who have undergone a previous wide local excision was once thought to have a high probability of being inaccurate due to disruption of the lymphatic channels by the initial surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/9\">",
"     9",
"    </a>",
"    ]. However, more recent studies suggest that SLN biopsy is still accurate and reflects the nodal status of the draining regional basin in the majority of patients who have had a previous wide local excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of SLN biopsy after a previous wide local excision is illustrated by the following retrospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 104 patients from M D Anderson, the SLN was identified in 103 (99 percent) and was positive in 18 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/10\">",
"       10",
"      </a>",
"      ]. Over a 51-month median follow-up period there were no nodal basin recurrences in any of the patients.",
"     </li>",
"     <li>",
"      In another series of 76 patients, the sentinel lymph node was successfully identified in 75 cases (98 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/12\">",
"       12",
"      </a>",
"      ]. In this study, 11 patients (15 percent) had a positive SLN biopsy. Among those with a negative SLN, only 3 of 64 (4 percent) subsequently developed regional lymph node recurrence in conjunction with a systemic recurrence, and one patient had an isolated regional recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strong consideration should be given to performing a sentinel lymph node biopsy in patients with isolated local recurrence or in transit disease, because of its prognostic significance and the potential for additional therapeutic options if the SLN biopsy is positive. Lymphatic mapping and SLN biopsy can be performed even in patients who have had a previous SLN biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with melanoma local recurrences are at high risk for the development of disseminated disease. In patients with positive regional lymph nodes, adjuvant high-dose interferon alfa may be recommended following surgical resection of the regional lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized clinical trials are not available to address the value of adjuvant immunotherapy in patients who are rendered disease-free following resection of a local recurrence. However, for patients who have undergone resection of a local recurrence and have no other evidence of disease, adjuvant therapy with high dose interferon alfa may be considered based upon the results in patients with resected positive regional lymph nodes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thick primary tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local radiation therapy has been used less commonly than surgery for treatment of local recurrence. Radiation has a limited role, but can provide long-term local control and meaningful palliation in patients who have failed first-line therapies. The role of radiation therapy in patients with local recurrence is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=see_link&amp;anchor=H15#H15\">",
"     \"Role of radiation therapy in the management of melanoma\", section on 'Cutaneous and lymph node metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intralesional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratumoral therapy may be considered in patients who not candidates for surgical resection. Studies on the use of intralesional therapy generally were done in studies that included patients with local recurrences, in transit metastases, or other skin metastases. Bacillus Calmette-Guerin (BCG),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    (IFNa), and interleukin 2 (IL-2) are the primary agents that have been used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCG &mdash; The first intralesional agent used in this manner was prepared from bacillus Calmette-Guerin (BCG). In an early report, 20 of 27 patients (74 percent) had an objective response with intratumoral BCG injections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/13\">",
"       13",
"      </a>",
"      ]. In a pooled analysis of 15 observational studies of intralesional BCG, complete and partial responses were seen in 19 and 26 percent, respectively, and 13 percent of patients with stage III melanoma were long-term survivors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/14\">",
"       14",
"      </a>",
"      ]. BCG dissemination with ulceration, skin necrosis, lymphadenitis, and abscess formation has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IFNa &mdash; The efficacy of intralesional injection of IFNa was shown in a study of 51 patients with at least one melanoma skin metastasis who received 10 MU of recombinant IFNa or 6 MU of highly purified natural IFNa three times weekly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/16\">",
"       16",
"      </a>",
"      ]. There were 24 complete or partial local responses (47 percent), the duration of which ranged from 2 to 18 months. Systemic anti-neoplastic responses were observed in nine patients (38 percent), with documented responses in lung and non-injected soft tissues.",
"     </li>",
"     <li>",
"      IL-2 &mdash; At least some data support a possible benefit for intratumoral IL-2 injection of a limited number of melanoma metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. In one study, 24 patients with primary melanoma and a single or multiple cutaneous or soft tissue metastases received intralesional injections (from 0.6 to 6 x 10(6) international units per dose, depending upon lesion size) two to three times weekly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/17\">",
"       17",
"      </a>",
"      ]. A complete response was seen in 209 of the 245 treated metastases, with a partial response in 21 others. Treatment was reasonably well tolerated.",
"     </li>",
"     <li>",
"      Herpes simplex virus 1 (HSV-1) &mdash; An engineered mutant HSV-1 strain that expresses GM-CSF was tested in 55 patients with metastatic melanoma, many with in transit metastases. Direct intratumoral injection of one lesion in each patient resulted an objective response in 26 percent of patients by RECIST criteria (",
"      <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"       table 2",
"      </a>",
"      ). Some durability of response was noted both in injected and uninjected lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/19\">",
"       19",
"      </a>",
"      ]. A randomized phase III trial is presently underway.",
"     </li>",
"     <li>",
"      Other intralesional approaches that are investigational include the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      in a gel containing the vasoconstrictor epinephrine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], and the use of dinitrochlorobenzene (DNCB) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/22\">",
"       22",
"      </a>",
"      ]. Electrochemotherapy uses a small electric current (electroporation, a form of electromotive drug administration) to increase drug delivery into the tumor; this approach has been used primarily with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34007/abstract/23-26\">",
"       23-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the responsiveness of cutaneous metastases to intralesional treatment, long-term survival is limited to the minority of patients that do not develop distant metastases. No trials have demonstrated an impact of intralesional therapy on survival. Except for BCG, none of the intralesional approaches has an established role in the routine management of patients with cutaneous metastases.",
"   </p>",
"   <p>",
"    While none of these intralesional approaches is usually utilized as initial therapy, they occasionally find a role in select patients who have significant medical comorbidities or have failed surgical and regional chemotherapeutic strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Isolated limb perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection is not an option for some patients because of the extensive nature of their local recurrences. For such patients, hyperthermic isolated limb perfusion (ILP) may be an effective treatment option if the recurrence is located on an extremity.",
"   </p>",
"   <p>",
"    Isolated limb perfusion is more commonly applied to patients with extensive in transit metastases. These patients predominate in most series. The technique and results with this approach in patients with advanced locoregional disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link&amp;anchor=H12#H12\">",
"     \"Cutaneous melanoma: Management of in transit metastases\", section on 'Isolated limb perfusion or infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Adjuvant ILP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for applying ILP in the adjuvant (ie, postoperative setting) is to eliminate any microscopic residual cells that may remain locoregionally. Although adjuvant limb perfusion decreases the incidence of both in transit and local recurrences, clinical trials have not demonstrated an improvement in survival. The results with adjuvant ILP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link\">",
"     \"Cutaneous melanoma: Management of in transit metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Isolated limb infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the technical complexities associated with hyperthermic isolated limb perfusion, investigators have examined intraarterial infusion of chemotherapy alone as an alternative. This technique and results in patients with in transit metastases and local recurrences is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link&amp;anchor=H12#H12\">",
"     \"Cutaneous melanoma: Management of in transit metastases\", section on 'Isolated limb perfusion or infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose bolus interleukin (IL)-2 is associated with tumor response in up to 50 percent of patients with cutaneous metastases from melanoma with many appearing to have long-term disease-free survival. This approach is associated with severe but transient toxicity, however, and is only appropriate in carefully selected circumstances.",
"   </p>",
"   <p>",
"    Systemic treatment of melanoma results in a complete response in only a small fraction of patients with disseminated disease. Such an approach is generally reserved for situations in which the local recurrence is not treatable by resection or regional perfusion or in which distant metastases are also present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8328?source=see_link\">",
"     \"Cytotoxic chemotherapy for metastatic melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local recurrences of melanoma following initial therapy may occur by a variety of mechanisms and generally are a harbinger of disseminated disease. Although the long-term prognosis for most patients is poor, aggressive therapy is warranted to minimize morbidity and potentially to increase survival. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanisms of local recurrence'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Local recurrence and survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a local recurrence and no other evidence of disease, we recommend surgical resection (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest lymphatic mapping and sentinel lymph node biopsy, with completion lymph node dissection if positive lymph nodes are identified (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have undergone resection of a local recurrence and have no other evidence of disease, we suggest adjuvant therapy with high-dose interferon alfa may be considered. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Adjuvant therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44711?source=see_link\">",
"       \"Adjuvant immunotherapy for melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a local recurrence and a limited disease burden elsewhere, we suggest surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unresectable disease of the extremities, but with minimal or no systemic disease, we suggest isolated limb perfusion or isolated limb infusion with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      if there is access to a center with adequate expertise in this technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link&amp;anchor=H12#H12\">",
"       \"Cutaneous melanoma: Management of in transit metastases\", section on 'Isolated limb perfusion or infusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a local recurrence who are not candidates for surgical resection and in whom isolated limb perfusion or infusion is either not available or not appropriate, we suggest intralesional therapy or radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=see_link&amp;anchor=H15#H15\">",
"       \"Role of radiation therapy in the management of melanoma\", section on 'Cutaneous and lymph node metastases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/1\">",
"      Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/2\">",
"      Kelly JW, Sagebiel RW, Calderon W, et al. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984; 200:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/3\">",
"      Karakousis CP, Balch CM, Urist MM, et al. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/4\">",
"      Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/5\">",
"      Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/6\">",
"      Le&oacute;n P, Daly JM, Synnestvedt M, et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/7\">",
"      Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg 1995; 21:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/8\">",
"      Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/9\">",
"      Kelemen PR, Essner R, Foshag LJ, Morton DL. Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma. J Am Coll Surg 1999; 189:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/10\">",
"      Gannon CJ, Rousseau DL Jr, Ross MI, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer 2006; 107:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/11\">",
"      Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 2003; 238:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/12\">",
"      Evans HL, Krag DN, Teates CD, et al. Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excision. Ann Surg Oncol 2003; 10:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/13\">",
"      Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Gu&eacute;rin and hyperthermic perfusion. Surg Gynecol Obstet 1979; 149:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/14\">",
"      Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/15\">",
"      Felix EL, Jessup JM, Cohen MH. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications. Arch Surg 1978; 113:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/16\">",
"      von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988; 61:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/17\">",
"      Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/18\">",
"      Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 2011; 104:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/19\">",
"      Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/20\">",
"      Holding JD, Lindup WE, Bowdler DA, et al. Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck. Br J Clin Pharmacol 1991; 32:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/21\">",
"      Oratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003; 13:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/22\">",
"      Cohen MH, Jessup JM, Felix EL, et al. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 1978; 41:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/23\">",
"      Gaudy C, Richard MA, Folchetti G, et al. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/24\">",
"      Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/25\">",
"      Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34007/abstract/26\">",
"      Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009; 16:191.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7607 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34007=[""].join("\n");
var outline_f33_13_34007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF LOCAL RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR LOCAL RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Width of resection margin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anatomic site and ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Timing of local recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LOCAL RECURRENCE AND SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Lymphatic mapping and SLN biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intralesional therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Isolated limb perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Adjuvant ILP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Isolated limb infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7607\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7607|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/4/29771\" title=\"table 1\">",
"      Melanoma recur temporal pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 2\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=related_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8328?source=related_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15450?source=related_link\">",
"      Imaging studies in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=related_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2183?source=related_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_13_34008="Nonalcoholic steatohepatitis II - medium power";
var content_f33_13_34008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Nonalcoholic steatohepatitis (NASH) (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is drop out of hepatocytes around a central vein with some scarring and inflammation in addition to fat-filled hepatocytes. Other hepatocytes are swollen and contain Mallory's hyaline. These changes are identical to those seen in alcoholic steatohepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34008=[""].join("\n");
var outline_f33_13_34008=null;
var title_f33_13_34009="Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth";
var content_f33_13_34009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34009/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/13/34009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant polycystic kidney disease (ADPKD) is a common disorder, occurring in approximately 1 in every 400 to 1000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is estimated that less than one-half of these cases will be diagnosed during the patient's lifetime, as the disease is often clinically silent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetics of ADPKD and the mechanisms of cyst growth will be reviewed here. Issues related to diagnosis and screening and of autosomal recessive polycystic kidney disease, which is a disease of children, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of genetic defects have been described, including frameshift, deletion and missense mutations in patients with ADPKD. Most families have an abnormality on chromosome 16 in the PKD1 locus that is tightly linked to the alpha-globin gene locus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Most of the remaining patients have a defect in the PKD2 locus on chromosome 4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. A few families have a defect unrelated to either locus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies suggested that PKD1 was responsible for 96 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Subsequent data suggest that, at least in Europe, the incidence is lower at about 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/7\">",
"     7",
"    </a>",
"    ]. Macroscopic cysts occur later in PKD2 disease as does end-stage renal disease (mean age 74 versus 54 years in PKD1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/13\">",
"     13",
"    </a>",
"    ]. As a result, false negative results are more likely when screening young subjects with this disorder (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     PKD gene products",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genes for both PKD1 and PKD2 have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. PKD1 and PKD2 encode proteins called polycystin-1 and polycystin-2, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. PKD1 is an extremely large and complex gene (46 exons) that generates a 14 kb mRNA, encoding a protein of over 4000 amino acids in length; PKD2 is smaller (15 exons) and encodes a protein a little smaller than 1000 amino acids in length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is of interest that the PKD1 gene is adjacent to one of the genes for tuberous sclerosis (TSC2), a different disorder that is also associated with cyst (angiomyolipoma) formation in the kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/14\">",
"     14",
"    </a>",
"    ]. TSC2 is located in a genomic region that is duplicated more proximally on chromosome 16 than PKD1. The duplicate areas encode transcripts homologous to the PKD1 transcript. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also genomic duplication of PKD1 (PKD1-like genes), thereby making screening PKD1 for mutations difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .) The PKD1-like genes encode proteins that are unlikely to be products of significance.",
"   </p>",
"   <p>",
"    A",
"    <span class=\"nowrap\">",
"     phenotype/genotype",
"    </span>",
"    correlation with both PKD1 and PKD2 is unclear. Overall, a large number of mutations have been described in both genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"     17",
"    </a>",
"    ]. A discussion of the",
"    <span class=\"nowrap\">",
"     genotype/phenotype",
"    </span>",
"    correlation can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunohistologic localization studies have made the following observations with respect to polycystin-1, although some disagree about the specificity of the antibodies used for these and other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/6,19\">",
"     6,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is localized in renal tubular epithelia, hepatic bile ductules, and pancreatic ducts, all sites of cyst formation in ADPKD",
"     </li>",
"     <li>",
"      It is an integral membrane protein, found primarily in plasma membranes but also in the primary cilium",
"     </li>",
"     <li>",
"      It is less abundant in adult than fetal epithelia",
"     </li>",
"     <li>",
"      It is overexpressed in most but not all cysts in kidneys from patients with ADPKD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies analyzing the proposed protein structure of polycystin-1 and its membrane localization among cells in culture suggest that this protein is involved in adhesive protein-protein, cell-cell, and cell-matrix interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As an example, polycystin-1 localizes to the lateral membranes of cells making cell-cell contact in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, polycystin may exist in a complex with E-cadherin and the catenins, proteins that are involved in cell adhesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/22\">",
"     22",
"    </a>",
"    ]. An abnormality in polycystin-1 may therefore impair cell-cell and cell-matrix interactions, leading to abnormal epithelial cell differentiation and the various phenotypic expressions of ADPKD. The demonstration of impaired in vitro tubulogenesis in cyst-derived cells from ADPKD kidneys is compatible with this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/23\">",
"     23",
"    </a>",
"    ]. A ligand for polycystin has not been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"     17",
"    </a>",
"    ]. However, polycystin 1 may modify activator protein-1 transcription factors, which are involved in regulation of cell proliferation and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/24\">",
"     24",
"    </a>",
"    ]. In mice, the time at which the PKD1 gene is inactivated determines the resulting phenotype, suggesting that the role of the PKD1 gene product depends on the stage of development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Inactivation of the PKD-1 gene prior to 13 days results in severe cystic disease whereas inactivation of the gene after 14 days results in a more indolent course with cyst development only after five months.",
"   </p>",
"   <p>",
"    The PKD2 gene product, polycystin-2, is involved in cell calcium signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17,27,28\">",
"     17,27,28",
"    </a>",
"    ]. Studies using polyclonal antisera suggest that the PKD2 gene product is expressed in the distal tubules, collecting duct, and thick ascending limb in normal fetal and adult kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]; it localizes to the endoplasmic reticulum and not the plasma membrane in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/31\">",
"     31",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/29\">",
"     29",
"    </a>",
"    ], reports. It is also localized to the primary cilium. Strong expression has been noted in some cysts from PKD1 and PKD2 kidneys.",
"   </p>",
"   <p>",
"    Since the clinical expressions of PKD1 and PKD2 are similar, it has been suggested that polycystin-1 and polycystin-2 interact in some common pathway(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/32\">",
"     32",
"    </a>",
"    ]. Several lines of evidence provide support for this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities in renal cilia from mutations in either gene may contribute to renal cyst formation, as PKD1 and PKD2 localize to renal cilia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Abnormal cilia function'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Polycystin-1 and -2 are expressed in similar cellular and subcellular locations, although the overlap is not uniform [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/6,17,19\">",
"       6,17,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polycystin-1 appears to activate the JAK-STAT pathway, thereby inducing cell cycle arrest [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/33\">",
"       33",
"      </a>",
"      ]. Polcystin-2 functions as an essential cofactor for this process. Activation of the pathway is prevented with mutations that disrupt polycystin-1 and polycystin-2 binding.",
"     </li>",
"     <li>",
"      Polycystin-1 and polycystin-2 interact via their carboxy terminal coiled domains [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/34\">",
"       34",
"      </a>",
"      ]. Perturbation of this interaction results from carboxy terminal variants arising from either naturally occurring pathogenic mutations, or through deletional and site-directed mutagenesis.",
"     </li>",
"     <li>",
"      Both polycystins appear to regulate G protein signaling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/6\">",
"       6",
"      </a>",
"      ]. The carboxy terminal end of polycystin-1 can bind heterotrimeric G proteins, with polycystin-2 interacting with polycystin-1 to antagonize signaling.",
"     </li>",
"     <li>",
"      Mechanical stimuli induce cleavage of the cytoplasmic tail of polycystin-1 (via regulated intramembrane proteolysis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/35\">",
"       35",
"      </a>",
"      ]. This protein fragment is then translocated into the nuclei, at which the AP-1 transcription pathway is activated. The translocation is regulated by polycystin-2, which interacts with polycystin-1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also suggestive evidence that the polycystins may function as ion channels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The deletion of the mouse homologue of PKDL, a human gene with strong homology to PKD1 and PKD2, results in significant defects of the kidney [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/36\">",
"       36",
"      </a>",
"      ]. Expression studies show that polycystin-L, the protein encoded by PKDL, functions as a cation channel that is permeable to calcium, sodium, and potassium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/37\">",
"       37",
"      </a>",
"      ]. In the kidney, it is predominantly localized to principal cells of inner medullary collecting ducts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interaction of PKD1 and PKD2 creates a new calcium-permeable non-selective cation current, although the exact role for PKD1 is unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/27\">",
"       27",
"      </a>",
"      ]. Such activity is not observed with either protein alone or with disease-associated mutant proteins incapable of heterodimerization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Focal disease and the 'second hit' hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One other feature that is unexplained is the variable phenotypic expression of the disease. Even though the genetic defect is present in all cells, cysts form in fewer than 10 percent of tubules and, within tubules, cystic dilatation is focal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/15,19,39\">",
"     15,19,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have shed some light on the possibility of needing a \"second hit\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/6,17,40\">",
"     6,17,40",
"    </a>",
"    ]. Examination of individual renal cysts from patients with the PKD1 defect showed that the cysts were monoclonal. Thus, cysts may form only when there is loss of the normal haplotype in the presence of an abnormal PKD1 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17,41\">",
"     17,41",
"    </a>",
"    ]. This concept is supported by the demonstration of loss of heterozygosity in the PKD1 region of chromosome 16 in humans, and by the development of renal and pancreatic cysts in mice homozygous for PKD1 mutations, but not in heterozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/42\">",
"     42",
"    </a>",
"    ]. Similar findings have been found in cysts from those with the PKD2 defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence in support of the \"second hit\" hypothesis comes from a study in mice in which the genes for PKD2 were deleted",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    were unstable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/44\">",
"     44",
"    </a>",
"    ]. The latter allele was designed to undergo homologous-recombination to form a null allele after birth. Mice with homozygote germ-line deletions of PKD2 died in utero with cardiac defects and cyst formation in nephrons and pancreatic ducts. By comparison, mice with both a germ-line deletion and an unstable allele had pancreatic ductal cysts and kidney cysts, resulting in renal failure and early death.",
"   </p>",
"   <p>",
"    The time at which the PKD-1 gene is inactivated may determine the resulting phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a murine model, inactivation of the PKD-1 gene prior to 13 days results in severe cystic disease whereas inactivation of the gene after 14 days results in a more indolent course with cyst development only after five months.",
"   </p>",
"   <p>",
"    It is unclear whether a second hit is absolutely required to initiate cyst formation. Rather, another possibility is that, once the cyst has begun, a second hit permits cyst expansion and progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Mechanism of cyst formation and growth'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF CYST FORMATION AND GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying mechanism by which cysts form remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/45\">",
"     45",
"    </a>",
"    ]. A number of theories have been proposed, including weakening of the tubular basement membranes or intratubular obstruction from hyperplastic cells, leading to secondary cyst formation. There has, however, been little evidence to support these hypotheses. Furthermore, the observation that human PKD cells but not normal renal epithelial cells can form cysts when grown in culture suggests a genetic defect that directly promotes cyst formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that abnormal cellular differentiation, maturation and apoptosis are responsible for the cyst formation in ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17,39,47,48\">",
"     17,39,47,48",
"    </a>",
"    ]. This could be initiated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    propagated via an initial germ line mutation plus a number of additional factors, including the second hit, mutations in the other ADPKD gene, mutations in non-ADPKD genes, as well as other events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Focal disease and the 'second hit' hypothesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The time at which the PKD-1 gene is inactivated may determine the resulting phenotype, suggesting the existence of a developmental switch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/25\">",
"     25",
"    </a>",
"    ]. In a murine model, inactivation of the PKD-1 gene prior to 13 days results in severe cystic disease whereas inactivation of the gene after 14 days results in a more indolent course with cyst development only after five months.",
"   </p>",
"   <p>",
"    However initiated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    promoted, abnormal cellular differentiation and maturation could promote cyst formation via many possible biochemical mechanisms. These include abnormal cell protein targeting, cyclic AMP activation, abnormal cilia function, and other possibilities:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Abnormal targeting of cell proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some human PKD cysts have Na-K-ATPase pumps partially located in the luminal membrane, rather than limited to the basolateral membrane where they normally mediate tubular sodium reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/49\">",
"     49",
"    </a>",
"    ]. The translocation of these pumps, which would favor sodium and water secretion into the cyst and cyst growth, appears to occur early in cyst development.",
"   </p>",
"   <p>",
"    How this happens is not clear. Studies in experimental cystic disease indicate that some Na-K-ATPase pumps are present in the luminal membrane of collecting tubule cells during normal development, suggesting that the abnormality in pump distribution in ADPKD may be a reflection of relatively undifferentiated cells lining the cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/50\">",
"     50",
"    </a>",
"    ]. Consistent with this hypothesis is the observation in humans that translocation also occurs in acquired renal cystic disease. Thus, the change in Na-K-ATPase polarity is probably a secondary event, perhaps due to cell dedifferentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of cyclic AMP and intracellular calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Derangements in cyclic AMP related to decreased intracellular calcium signaling may underlie the development of cysts via increased fluid secretion and cell proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Strategies that target calcium homeostasis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cAMP signaling have been studied in rodent models of PKD with the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/28,55-57\">",
"     28,55-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of a vasopressin V2 receptor antagonist prevents renal enlargement and inhibits cystogenesis by decreasing renal cAMP levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link&amp;anchor=H19#H19\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Modulation of the intracellular calcium concentration with calcium channel blockers or triptolide, a polycystin-2 agonist that induces calcium release, changes the rate of cell proliferation in cysts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcimimetics inhibit cyst growth in late [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/57\">",
"       57",
"      </a>",
"      ] but not in early stages of disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mammalian target of rapamycin (mTOR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of the mammalian target of rapamycin (mTOR) protein may contribute to cyst growth in PKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The inhibition of mTOR with rapamycin preserves renal function and inhibits epithelial cell proliferation and fibrosis in mouse models of ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Clinical studies have suggested that mTOR inhibitors may limit the increase in liver and kidney volumes in patients with ADPKD, but do not appear to preserve kidney function, at least over the short term. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link&amp;anchor=H22#H22\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Mammalian target of rapamycin (mTOR)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abnormal cilia function",
"    </span>",
"    &nbsp;&mdash;&nbsp;A leading hypothesis is that abnormalities in renal cilia due to polycystin mutations contribute to renal cyst formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17,63-66\">",
"     17,63-66",
"    </a>",
"    ]. Support for this is provided in part by murine models of renal cystic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], as well as other animal models, in which there appears to be an association between certain genetic defects and abnormalities in cilia formation and function, left-right axis determination, and cyst development. In addition to PKD1 and PKD2, nephronophthisis genes localize to primary cilia of renal tubular cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alterations in cilia function in polycystic kidneys may directly interfere with the ability of renal epithelium to correctly sense luminal flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/69\">",
"     69",
"    </a>",
"    ]. As an example, increased calcium influx in response to physiologic fluid flow does not occur in renal epithelial monolayers consisting of either PKD1 null cells or cells treated with blocking antibodies to PKD1 or PKD2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/63\">",
"     63",
"    </a>",
"    ]. Dysregulated tissue growth and renal cysts may therefore result from the polycystic kidney's attempt to compensate for a perceived lack of fluid flow. In particular, intracellular calcium flux may couple with cyclic AMP signaling pathways, resulting in dysregulated cyst growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'PKD gene products'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Cyst growth'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Insight into the connection between abnormal cilia function and dysregulated cell growth may also be provided by observations that cilia are connected to centrosomal structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/64\">",
"     64",
"    </a>",
"    ]. The centrosome, in turn, may have significant role in the regulation of cell-cycle progression and control, with abnormalities in the",
"    <span class=\"nowrap\">",
"     cilia/centrosome",
"    </span>",
"    apparatus possibly resulting in dysregulated growth. Additional support for this is provided by the observation that most of the proteins associated with the Bardet-Biedl syndrome (which has",
"    <span class=\"nowrap\">",
"     cystic/dysplasia),",
"    </span>",
"    localize to centrosomal structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abnormalities in epithelial cell growth and tubule elongation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of proto-oncogenes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transcription factors, and subsequent tubular hyperplasia may play an important role in epithelial cell growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. As an example, overexpression of prothymosin alpha, which may be an oncoprotein, induces polycystic kidney disease in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The loss of PKD1 gene product, polycystin-1 may cause abnormalities in planar cell polarity, which causes defective tubule elongation, resulting in dilatation and cyst formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiogenesis may play a role in cyst growth and progression in ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. This is supported by the observation that renal and hepatic cysts have elevated levels of vascular endothelial growth factor (VEGF) and other cytokines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. However, the role of VEGF is unclear, since experimental data suggest that blockade of the VEGF receptor promotes cyst formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cyst growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cysts are derived from different nephron segments and the epithelial cells lining the cysts appear to retain their transport functions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/15,39\">",
"     15,39",
"    </a>",
"    ]. Sodium concentrations vary within different cysts, generally being under 60",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or over 75",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/82\">",
"     82",
"    </a>",
"    ]. It has been proposed that the high-sodium cysts might derive from the proximal tubule (particularly in cysts with a sodium concentration similar to that in the plasma) while the low-sodium cysts might derive from the distal nephron (the site at which a low urine sodium concentration is normally achieved).",
"   </p>",
"   <p>",
"    However, careful histological examination has been unable to confirm this relationship, as there is a spectrum of cyst sodium concentrations, not just high or low values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/82\">",
"     82",
"    </a>",
"    ]. The high sodium cysts do have much shallower tight junctions between adjacent cells; this observation suggests that these cysts are unable to maintain a high concentration gradient between the cyst fluid and plasma because they are more permeable to passive backflux of sodium into the lumen down a favorable concentration gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/82\">",
"     82",
"    </a>",
"    ]. Fluid secretion in the cysts may be mediated in part by the cystic fibrosis transmembrane conductance regulator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early cysts begin as dilatations in intact tubules that are in contact with the nephron and fill by glomerular filtration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/15,39\">",
"     15,39",
"    </a>",
"    ]. However, enlarging cysts lose their connection to functioning nephrons, presumably due to fibrosis in the surrounding interstitium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/15,39\">",
"     15,39",
"    </a>",
"    ]. Cyst growth in this setting results from secretion of fluid into the cysts (rather than by glomerular filtration) and is associated with hyperplasia of the cyst epithelium that may reflect underlying maturational arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/2,39\">",
"     2,39",
"    </a>",
"    ]. How this occurs is not known, but PKD cysts secrete fluid in vitro and a substance or substances in human cyst fluid promotes fluid secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/84\">",
"     84",
"    </a>",
"    ] and can cause cyst formation when added to renal tubular cells in culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/46\">",
"     46",
"    </a>",
"    ]. These results provide a potential explanation for disease progression in ADPKD, although the origin of the growth factor(s) in the cyst fluid is uncertain. In vitro studies suggest that the rate of cyst fluid accumulation varies between 26 and 475 mL per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cystic fibrosis transmembrane conductance regulator (CFTR) has been reported in the apical membranes of ADPKD cells. This channel functions as a cyclic AMP-dependent chloride channel, but it is unclear whether it contributes to cyst growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/83,85\">",
"     83,85",
"    </a>",
"    ]. Suggestive evidence for an important pathogenic role for CFTR is provided by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with both ADPKD and cystic fibrosis may have less severe cystic disease of the kidney and liver compared to family members with ADPKD but without cystic fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/86\">",
"       86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unlike normal renal epithelial cells, in vitro growth of ADPKD cells as well as enlargement of associated cysts is markedly stimulated by the addition of cAMP to the culture medium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CFTR inhibitors slow cyst growth in in vitro and in vivo models of PKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, double mutant mice, which are homozygous for an autosomal recessive cystic gene and have both CFTR genes deleted, are not protected from cystic disease and die of massively enlarged kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34009/abstract/89\">",
"     89",
"    </a>",
"    ]. This suggests that either the autosomal recessive murine kidney model is physiologically different from ADPKD in humans or that the CFTR gene does not significantly contribute to cyst growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/24/38277?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant polycystic kidney disease (ADPKD) occurs in approximately 1 in every 400 to 1000 live births. Fewer than one-half of cases are diagnosed during the patient's lifetime, as the disease is often clinically silent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple causative genetic defects have been described, most of which are within the PKD1 locus on chromosome 16, resulting in PKD1 disease. A smaller number of patients have a defect in the PKD2 locus on chromosome 4 (resulting in PKD2 disease) and a few families have an undefined defect. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PKD1 and PKD2 encode proteins called polycystin-1 and polycystin-2, respectively. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polycystin-1 is a membrane protein localized at sites of cyst formation, including renal tubular epithelia, hepatic bile ductules, and pancreatic ducts. Possible roles of polycystin-1 include the regulation of protein-protein, cell-cell, and cell-matrix interactions, and of intracellular signaling pathways involved in the regulation of cell proliferation and survival. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polycystin-2 is expressed in the distal tubules, collecting duct, and thick ascending limb and is involved in cell calcium signaling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polycystin-1 and polycystin-2 also interact in a common pathways and function together as an important regulator of calcium influx as a nonselective calcium ion channel. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the inheritance of an abnormal PKD1 gene, cyst formation appears to form only when there is a second, acquired somatic loss of the normal haplotype; this is referred to as the second hit hypothesis. As a result, although the genetic defect is present in all cells, cysts form in fewer than 10 percent of tubules and cystic dilatation is focal within tubules. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Focal disease and the 'second hit' hypothesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which cysts form is unclear. A leading theory is that abnormal cellular differentiation, maturation and apoptosis are operative. Cyst formation may result from multiple aberrant processes including abnormal cell protein targeting (as, for example, Na-K-ATPase); cyclic AMP activation; and abnormal cilia function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of cyst formation and growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevations in cyclic AMP related to decreased intracellular calcium signaling may enhance cyst formation by increasing fluid secretion and cell proliferation. Vasopressin V2 receptor antagonists, increases in the intracellular calcium concentration, and calcimimetics all may decrease cyst growth. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Role of cyclic AMP and intracellular calcium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities in renal cilia function contribute to renal cyst formation in animal models, possibly by decreasing the ability of renal epithelium to sense luminal flow rates. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Abnormal cilia function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other mechanisms that may contribute to cyst growth include unregulated epithelial cell growth due to the activation of proto-oncogenes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transcription factors, and increased angiogenesis due to elevated levels of vascular endothelial growth factor (VEGF) and other cytokines. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Abnormalities in epithelial cell growth and tubule elongation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Angiogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early cysts begin as dilatations in intact tubules that are in contact with the nephron, however enlarging cysts lose their connection to functioning nephrons. Cyst growth in this setting results from secretion of fluid into the cysts and is associated with hyperplasia of the cyst epithelium. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cyst growth'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/1\">",
"      Davies F, Coles GA, Harper PS, et al. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991; 79:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/2\">",
"      Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/3\">",
"      Parfrey PS, Bear JC, Morgan J, et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/4\">",
"      Breuning MH, Reeders ST, Brunner H, et al. Improved early diagnosis of adult polycystic kidney disease with flanking DNA markers. Lancet 1987; 2:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/5\">",
"      Arnaout MA. The vasculopathy of autosomal dominant polycystic kidney disease: insights from animal models. Kidney Int 2000; 58:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/6\">",
"      Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/7\">",
"      Peters DJ, Spruit L, Saris JJ, et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 1993; 5:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/8\">",
"      Pei Y, He N, Wang K, et al. A spectrum of mutations in the polycystic kidney disease-2 (PKD2) gene from eight Canadian kindreds. J Am Soc Nephrol 1998; 9:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/9\">",
"      Torra R, Viribay M, Teller&iacute;a D, et al. Seven novel mutations of the PKD2 gene in families with autosomal dominant polycystic kidney disease. Kidney Int 1999; 56:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/10\">",
"      Daoust MC, Reynolds DM, Bichet DG, Somlo S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics 1995; 25:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/11\">",
"      de Almeida E, Martins Prata M, de Almeida S, Lavinha J. Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3. Nephrol Dial Transplant 1999; 14:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/12\">",
"      Reed B, McFann K, Kimberling WJ, et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis 2008; 52:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/13\">",
"      Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/14\">",
"      The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994; 77:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/15\">",
"      Gardner KD Jr, Glew RH, Evan AP, et al. Why renal cysts grow. Am J Physiol 1994; 266:F353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/16\">",
"      Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/17\">",
"      Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005; 67:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/18\">",
"      Wilson PD. Polycystin: new aspects of structure, function, and regulation. J Am Soc Nephrol 2001; 12:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/19\">",
"      Geng L, Segal Y, Peissel B, et al. Identification and localization of polycystin, the PKD1 gene product. J Clin Invest 1996; 98:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/20\">",
"      Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995; 81:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/21\">",
"      Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, et al. Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci U S A 1997; 94:6397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/22\">",
"      Huan Y, van Adelsberg J. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest 1999; 104:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/23\">",
"      Carone FA, Nakamura S, Bacallao R, et al. Impaired tubulogenesis of cyst-derived cells from autosomal dominant polycystic kidneys. Kidney Int 1995; 47:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/24\">",
"      Le NH, van der Wal A, van der Bent P, et al. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005; 16:2724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/25\">",
"      Piontek K, Menezes LF, Garcia-Gonzalez MA, et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 2007; 13:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/26\">",
"      Kim E, Walz G. Sensitive cilia set up the kidney. Nat Med 2007; 13:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/27\">",
"      Hanaoka K, Qian F, Boletta A, et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 2000; 408:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/28\">",
"      Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/29\">",
"      Foggensteiner L, Bevan AP, Thomas R, et al. Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 gene. J Am Soc Nephrol 2000; 11:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/30\">",
"      Chauvet V, Qian F, Boute N, et al. Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 2002; 160:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/31\">",
"      Cai Y, Maeda Y, Cedzich A, et al. Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 1999; 274:28557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/32\">",
"      Murcia NS, Sweeney WE Jr, Avner ED. New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 1999; 55:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/33\">",
"      Bhunia AK, Piontek K, Boletta A, et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002; 109:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/34\">",
"      Qian F, Germino FJ, Cai Y, et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 1997; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/35\">",
"      Chauvet V, Tian X, Husson H, et al. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 2004; 114:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/36\">",
"      Nomura H, Turco AE, Pei Y, et al. Identification of PKDL, a novel polycystic kidney disease 2-like gene whose murine homologue is deleted in mice with kidney and retinal defects. J Biol Chem 1998; 273:25967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/37\">",
"      Chen XZ, Vassilev PM, Basora N, et al. Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature 1999; 401:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/38\">",
"      Basora N, Nomura H, Berger UV, et al. Tissue and cellular localization of a novel polycystic kidney disease-like gene product, polycystin-L. J Am Soc Nephrol 2002; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/39\">",
"      Grantham JJ. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances. Am J Kidney Dis 1996; 28:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/40\">",
"      Qian F, Watnick TJ, Onuchic LF, Germino GG. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996; 87:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/41\">",
"      Brasier JL, Henske EP. Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest 1997; 99:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/42\">",
"      Lu W, Peissel B, Babakhanlou H, et al. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 1997; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/43\">",
"      Pei Y, Watnick T, He N, et al. Somatic PKD2 mutations in individual kidney and liver cysts support a \"two-hit\" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999; 10:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/44\">",
"      Wu G, Markowitz GS, Li L, et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 2000; 24:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/45\">",
"      Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/46\">",
"      Ye M, Grant M, Sharma M, et al. Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol 1992; 3:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/47\">",
"      Woo DD, Miao SY, Pelayo JC, Woolf AS. Taxol inhibits progression of congenital polycystic kidney disease. Nature 1994; 368:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/48\">",
"      Boca M, Distefano G, Qian F, et al. Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J Am Soc Nephrol 2006; 17:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/49\">",
"      Carone FA, Nakamura S, Caputo M, et al. Cell polarity in human renal cystic disease. Lab Invest 1994; 70:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/50\">",
"      Avner ED, Sweeney WE Jr, Nelson WJ. Abnormal sodium pump distribution during renal tubulogenesis in congenital murine polycystic kidney disease. Proc Natl Acad Sci U S A 1992; 89:7447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/51\">",
"      Grantham JJ, Ye M, Gattone VH 2nd, Sullivan LP. In vitro fluid secretion by epithelium from polycystic kidneys. J Clin Invest 1995; 95:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/52\">",
"      Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003; 64:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/53\">",
"      Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/54\">",
"      Torres VE. Type II calcimimetics and polycystic kidney disease: unanswered questions. J Am Soc Nephrol 2009; 20:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/55\">",
"      Nagao S, Nishii K, Yoshihara D, et al. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 2008; 73:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/56\">",
"      Leuenroth SJ, Bencivenga N, Igarashi P, et al. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 2008; 19:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/57\">",
"      Gattone VH 2nd, Chen NX, Sinders RM, et al. Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol 2009; 20:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/58\">",
"      Wang X, Harris PC, Somlo S, et al. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrol Dial Transplant 2009; 24:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/59\">",
"      Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/60\">",
"      Torres VE, Boletta A, Chapman A, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010; 5:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/61\">",
"      Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010; 21:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/62\">",
"      Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012; 23:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/63\">",
"      Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/64\">",
"      Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004; 15:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/65\">",
"      Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens 2009; 18:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/66\">",
"      Harris PC. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol 2009; 20:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/67\">",
"      Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002; 13:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/68\">",
"      Gallagher AR, Hoffmann S, Brown N, et al. A truncated polycystin-2 protein causes polycystic kidney disease and retinal degeneration in transgenic rats. J Am Soc Nephrol 2006; 17:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/69\">",
"      Joly D, Hummel A, Ruello A, Knebelmann B. Ciliary function of polycystins: a new model for cystogenesis. Nephrol Dial Transplant 2003; 18:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/70\">",
"      Ansley SJ, Badano JL, Blacque OE, et al. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature 2003; 425:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/71\">",
"      Li JB, Gerdes JM, Haycraft CJ, et al. Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. Cell 2004; 117:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/72\">",
"      Herrera GA. C-erb B-2 amplification in cystic renal disease. Kidney Int 1991; 40:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/73\">",
"      Arnould, T, Kim E, Gruning, W, et al. Cellular activation triggered by PKD2 (abstract). J Am Soc Nephrol 1998; 9:370A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/74\">",
"      Li KJ, Shiau AL, Chiou YY, et al. Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease. Kidney Int 2005; 67:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/75\">",
"      Gattone VH 2nd. Prothymosin alpha as a cystogen. Kidney Int 2005; 67:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/76\">",
"      Luyten A, Su X, Gondela S, et al. Aberrant regulation of planar cell polarity in polycystic kidney disease. J Am Soc Nephrol 2010; 21:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/77\">",
"      Patel V. Balancing the Wnts in polycystic kidney disease. J Am Soc Nephrol 2010; 21:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/78\">",
"      Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 2001; 60:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/79\">",
"      Wei W, Popov V, Walocha JA, et al. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 2006; 70:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/80\">",
"      Nichols MT, Gidey E, Matzakos T, et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 2004; 40:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/81\">",
"      McGrath-Morrow S, Cho C, Molls R, et al. VEGF receptor 2 blockade leads to renal cyst formation in mice. Kidney Int 2006; 69:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/82\">",
"      Gardner KD Jr, Burnside JS, Skipper BJ, et al. On the probability that kidneys are different in autosomal dominant polycystic disease. Kidney Int 1992; 42:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/83\">",
"      Davidow CJ, Maser RL, Rome LA, et al. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996; 50:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/84\">",
"      Grantham JJ, Ye M, Davidow C, et al. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 6:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/85\">",
"      Hanaoka K, Devuyst O, Schwiebert EM, et al. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 1996; 270:C389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/86\">",
"      O'Sullivan DA, Torres VE, Gabow PA, et al. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/87\">",
"      Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/88\">",
"      Yang B, Sonawane ND, Zhao D, et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34009/abstract/89\">",
"      Nakanishi K, Sweeney WE Jr, Macrae Dell K, et al. Role of CFTR in autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2001; 12:719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1682 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34009=[""].join("\n");
var outline_f33_13_34009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PKD gene products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Focal disease and the 'second hit' hypothesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF CYST FORMATION AND GROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Abnormal targeting of cell proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of cyclic AMP and intracellular calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mammalian target of rapamycin (mTOR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abnormal cilia function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abnormalities in epithelial cell growth and tubule elongation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9433?source=related_link\">",
"      Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_13_34010="Radioiodine treatment of differentiated thyroid cancer";
var content_f33_13_34010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radioiodine treatment of differentiated thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34010/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34010/contributors\">",
"     R Michael Tuttle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34010/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34010/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/13/34010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/13/34010/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/13/34010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioiodine (131-I) therapy has been used in the management of patients with well-differentiated (papillary or follicular) thyroid cancer since the 1940s. Thyroid tissue has a unique ability to take up iodine from blood. Like iodine, radioiodine is taken up and concentrated in thyroid follicular cells because they have a membrane sodium-iodide transporter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/1\">",
"     1",
"    </a>",
"    ]. Compared with normal thyroid follicular cells, thyroid cancer cells have reduced expression of the transporter, which may account for the low 131-I uptake in thyroid cancer tissue.",
"   </p>",
"   <p>",
"    131-I causes acute thyroid-cell death by emission of short path-length (1 to 2 mm) beta rays. The uptake of 131-I by thyroid tissue can be visualized by scanning to detect the gamma radiation that is also emitted by the isotope. 131-I must be taken up by thyroid tissue to be effective. As a result, it is of no value in patients whose thyroid cancers do not concentrate iodide, for example patients with medullary cancer, lymphoma, or anaplastic cancer.",
"   </p>",
"   <p>",
"    Radioiodine therapy for differentiated thyroid cancer will be reviewed here. Surgery, the primary therapy for differentiated thyroid cancer, and an overview of the management of thyroid cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41064?source=see_link\">",
"     \"Surgical treatment of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for 131-I administration after thyroidectomy in patients with differentiated thyroid cancer include ablation of residual normal thyroid tissue, adjuvant therapy of subclinical micrometastatic disease, and treatment of clinically apparent residual or metastatic thyroid cancer. In addition, 131-I is used diagnostically for localization of uptake before ablation or therapy. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnostic scanning'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The efficacy of radioiodine for both scanning and treatment depends upon patient preparation, tumor-specific characteristics, sites of disease, and dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment of residual thyroid tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for treatment of residual thyroid tissue with 131-I is to destroy any remnant normal thyroid tissue remaining after total thyroidectomy (remnant ablation). This will, in turn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Destroy subclinical, microscopic foci of disease remaining after surgery (adjuvant therapy)",
"     </li>",
"     <li>",
"      Minimize the risk of development of de novo papillary thyroid cancers in at risk patients (eg, history of head and neck irradiation, genetic predisposition syndromes)",
"     </li>",
"     <li>",
"      Improve the specificity of measurements of serum thyroglobulin as a tumor marker",
"     </li>",
"     <li>",
"      Increase the specificity of 131-I scanning for detection of recurrent or metastatic disease by eliminating uptake by residual normal tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of randomized, controlled trials, there has been considerable disagreement about the role of 131-I ablation, particularly in younger patients (&lt;age 45) with low-risk disease (ie, no soft tissue invasion and no distant metastases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/16/14599?source=see_link\">",
"     \"Clinicopathologic staging of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence from retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] and a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/5\">",
"     5",
"    </a>",
"    ] have suggested that 131-I ablation is associated with a reduction in the 10-year risk of recurrence by as much as 50 percent, a decrease in mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and a 3 percent decreased risk of metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/5\">",
"     5",
"    </a>",
"    ]. However, mortality benefit was only seen among patients whose primary tumors were at least 1 to 1.5 cm in diameter, multicentric, with cervical lymph node metastases, or who had soft tissue invasion at diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef58786 \" href=\"mobipreview.htm?43/45/44766\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast, other studies have not observed benefit. At the Mayo Clinic, there were no differences in mortality or recurrence rates in the decades when 131-I was rarely given (1940 to 1969) and the decades (1980 to 1999) when half of the patients received 131-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, updated systematic reviews and meta-analyses of the effectiveness of RAI in low-risk patients failed to find a benefit with regard to either overall recurrence rate or disease-specific mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A statistically significant decrease in the risk of distant metastases was seen.",
"   </p>",
"   <p>",
"    However, an important limitation of the meta-analyses is the lack of a consistent definition of \"low risk\" across individual studies. One example of a multicenter, prospective, data collection collaborative group that risk stratifies patients on a systematic staging system is the National Thyroid Cancer Treatment Cooperative Study Group, a multicenter thyroid cancer registry that has analyzed the outcomes of nearly 3000 patients with differentiated thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/9\">",
"     9",
"    </a>",
"    ]. Because of the careful risk stratification used in this study, it is possible to identify specific patient and tumor characteristics that suggest that radioiodine may be beneficial. As an example, the relative risk of death in the absence of postoperative radioiodine therapy was 43 percent higher in high-risk patients (Stage III and IV in the National Thyroid Cancer Treatment Cooperative Study Group staging system) (",
"    <a class=\"graphic graphic_table graphicRef67832 \" href=\"mobipreview.htm?34/51/35644\">",
"     table 1",
"    </a>",
"    ), but not low-risk patients. In multivariate analysis, RAI ablation was associated with a significant improvement in overall survival without a significant impact on disease-specific survival or disease-free survival in Stage II patients (",
"    <a class=\"graphic graphic_table graphicRef67832 \" href=\"mobipreview.htm?34/51/35644\">",
"     table 1",
"    </a>",
"    ). No overall survival benefit, disease-specific survival rate, or disease-free survival was seen in Stage I patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Residual tumor and metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goal of radioiodine therapy is to destroy clinically apparent macroscopic disease that is not amenable to surgical therapy. Radioiodine treatment of residual disease and metastatic disease may reduce the risk of recurrence and mortality, especially in small volume disease that is RAI avid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Residual tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one report of 1355 thyroid cancer patients, 131-I treatment of those with local or regional residual disease post-thyroidectomy decreased the 30-year recurrence and disease-specific mortality rates by about 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/4\">",
"     4",
"    </a>",
"    ]. In other studies, treatment of regional nodal metastases with at least 8000 to 10,000 cGy resulted in a complete response in 75 to 80 percent of patients; this may be difficult to achieve in patients with bulky disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Therefore, we recommend radioiodine treatment of RAI avid residual tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated for 131-I-concentrating pulmonary metastases, which occur in about 5 percent of cases of differentiated thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/12\">",
"     12",
"    </a>",
"    ], have a five-year survival rate of 60 percent compared with 30 percent in those whose tumors do not concentrate 131-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11\">",
"     11",
"    </a>",
"    ]. Long-term survival is highest in patients with pulmonary metastases seen on 131-I scans, but not chest x-ray or computed tomography. Patients with micronodular disease respond better than those with macronodular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, in one study, only 2 of 12 patients with micronodular disease had a complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/12\">",
"     12",
"    </a>",
"    ], perhaps because metastases smaller than 1 mm in size are not completely destroyed by 131-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/15\">",
"     15",
"    </a>",
"    ]. Suggested dosing is found below (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Radioiodine dose (activity)'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients who have metastatic pulmonary nodules seen on chest x-ray but not detected by 131-I scanning may rarely respond to large doses of 131-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/16\">",
"     16",
"    </a>",
"    ]. In general, however, radioiodine therapy is not helpful in treating disease that is not seen on a diagnostic scan but is visualized on a post-treatment scan, likely due to the fact that an insufficient amount of radioiodine was incorporated by the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skeletal metastases are often seen on 131-I scans, but do not concentrate 131-I very well; complete resolution of disease occurs in fewer than 10 percent of treated patients, and partial remission in only 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metastatic lesions that are positive on FDG PET scanning are usually quite refractory to RAI therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/18\">",
"     18",
"    </a>",
"    ], since there is often a dichotomy between FDG avidity and 131-I avidity.",
"   </p>",
"   <p>",
"    The benefits and dose limits of 131-I therapy for metastatic disease were evaluated in a retrospective analysis of 444 patients treated between 1953 and 1994 (analysis of whole body iodine scans and conventional radiographs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/19\">",
"     19",
"    </a>",
"    ]. Forty-three percent of the 295 patients with radioiodine uptake achieved resolution of RAI avid metastases on iodine scan and negative conventional radiographs. Additional features of patients in this group included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They were more likely to be younger with differentiated tumors",
"     </li>",
"     <li>",
"      96 percent of these patients were given cumulative doses of 100 to 600 mCi (3700 to 22,000 megabecquerel [MBq])",
"     </li>",
"     <li>",
"      7 percent had a recurrence",
"     </li>",
"     <li>",
"      10-year survival was 92 percent in this group, compared with only 19 percent in patients who did not achieve resolution of the RAI avid metastatic lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, most recommendations regarding indications for radioiodine remnant ablation were based upon the American Joint Committee on Cancer staging system, the National Thyroid Cancer Treatment Cooperative Study Group staging system, or other clinico-pathologic staging systems. In 2009, The American Thyroid Association (ATA) published revised guidelines on the role of postoperative radioiodine ablation (",
"    <a class=\"graphic graphic_table graphicRef51570 \" href=\"mobipreview.htm?17/38/18029\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/20\">",
"     20",
"    </a>",
"    ]. These guidelines make recommendations based upon the clinico-pathologic features of each case, rather than a specific staging system. We agree with the guidelines as outlined below.",
"   </p>",
"   <p>",
"    We currently recommend postoperative radioiodine ablation for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with known distant metastases, gross extrathyroidal extension of the tumor regardless of tumor size, or primary tumor size &gt;4 cm even in the absence of other high-risk features.",
"     </li>",
"     <li>",
"      Select patients with tumor size 1 to 4 cm confined to the thyroid, who have documented lymph node metastases or other higher-risk features (eg, vascular invasion, more aggressive histologic subtypes, such as tall cell, columnar cell, insular, or poorly differentiated histologies) when the combination of age, tumor size or multifocality, lymph node status, and individual histology predicts an intermediate to high risk of recurrence or death from thyroid cancer. In the absence of evidence supporting survival benefit for all of the factors listed, the ATA recognizes the importance of clinical judgment and an individualized approach to care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of a proven benefit on either disease-free survival or recurrence, we do not routinely recommend RAI ablation for patients with unifocal cancer &lt;1 cm without other high-risk features (distant metastases, vascular invasion, gross extrathyroidal extension, worrisome histologic subtypes, and possibly lymph node metastases) or for patients with multifocal cancer when all foci are &lt;1 cm and there are no other high-risk features.",
"   </p>",
"   <p>",
"    Recommendations for radioiodine dose are reviewed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Radioiodine dose (activity)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192459723\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and breastfeeding are absolute contraindications to radioiodine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/21\">",
"     21",
"    </a>",
"    ]. Fetal thyroid tissue is functional by 10 to 12 weeks and could be destroyed by the radioiodine, resulting in cretinism. Radioiodine should only be administered if a woman has a negative pregnancy test 72 hours before treatment is given, or the possibility of pregnancy is excluded by a careful history. There is increased sodium iodide symporter activity in estrogenized breast tissue. Breastfeeding should be stopped at least six to eight weeks prior to radioiodine therapy so as to reduce uptake of radioiodine by breast tissue. There are reports of utilization of dopamine agonist drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    to decrease serum prolactin and hence shorten the time that is required before 131-I can be administered safely to lactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMEN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioiodide uptake by thyroid tissue is stimulated by TSH and is suppressed by increased endogenous iodide stores. Thus, after thyroidectomy or cessation of thyroxine (T4) therapy, the patient's serum T4 concentration must decline sufficiently to allow the serum TSH concentration to rise to above 25 to 30",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thyroid hormone withdrawal remains the standard approach to raising TSH levels for adequate radioiodine uptake in the setting of 131-I treatment of residual tumor or metastatic disease. However, two small prospective studies suggest that rhTSH stimulated RAI therapy is effective in destroying microscopic metastatic disease, typically in cervical nodes or pulmonary micrometastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/23\">",
"     23",
"    </a>",
"    ], and is associated with similar five-year survival as thyroid hormone withdrawal in the setting of macroscopic RAI avid distant metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/24\">",
"     24",
"    </a>",
"    ]. We use recombinant TSH for routine RAI remnant ablation and follow-up scanning, unless the patient has known gross residual disease, distant metastases, or is expected to need subsequent radioiodine therapy (that would require thyroid hormone withdrawal).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Thyroid hormone withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;For years, the traditional approach to thyroid hormone withdrawal has been to discontinue the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    for approximately six weeks before rechecking the TSH and proceeding with RAI ablation or scanning. However, this approach was questioned by two studies that demonstrated an adequate rise in serum TSH following discontinuation of levothyroxine for 11 to 28 days in one study and 9 to 29 days in another study (mean 17 to 18 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To minimize the symptoms of hypothyroidism resulting from the traditional six-week withdrawal of T4, it is common to give the shorter-acting hormone triiodothyronine (T3,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/51/1846?source=see_link\">",
"     liothyronine",
"    </a>",
"    ) in doses of 25 mcg two to three times per day for the first two to three weeks after stopping T4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/27\">",
"     27",
"    </a>",
"    ]. Lower doses (eg, 10 to 12.5 mcg two or three times per day) should be used in elderly patients and those with ischemic heart disease. After cessation of T3, the serum TSH concentration should rise to 25 to 30",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    within one to two weeks. Thus, the interval during which the patient receives no thyroid hormone is shortened. However, one randomized controlled trial found no symptomatic benefit of T3 during thyroid hormone withdrawal and confirmed that a two to three week period of withdrawal was adequate time duration to see a sufficient rise in TSH to allow RAI ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another strategy to minimize hypothyroid symptoms in patients already taking T4 is to reduce the dose of oral T4 by 50 percent for approximately one month rather than stopping it entirely. In one study, the majority of patients taking half-dose T4 achieved a serum TSH concentration of 25 to 30",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    by five weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, their hypothyroid symptoms were milder than a group of patients undergoing standard T3 withdrawal.",
"   </p>",
"   <p>",
"    Whatever thyroid hormone withdrawal preparative regimen is used, serum TSH should be measured immediately before any 131-I is given to confirm that the concentration is high. Our current approach is to reduce the dose of oral T4 by 50 percent for four weeks and then discontinue the LT4 for one week prior to administration of RAI. Of course, the routine use of rhTSH as our method of choice for routine RAI ablation in most patients makes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    withdrawal unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recombinant hTSH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism can be avoided altogether by administering recombinant human TSH (rhTSH, thyrotropin alfa) before administration of 131-I for thyroid remnant ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In randomized trials and a meta-analysis, short-term rates of successful remnant ablation were similar after withdrawal of thyroid hormone or after administration of rhTSH (91 to 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. The results of large randomized trials published after the meta-analysis also support these findings. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial, 752 patients with low-risk differentiated thyroid cancer (papillary or follicular, TNM stage T1 [&lt;1 cm] and N1 or NX, T1 &gt;1 to 2 cm with any N, or T2N0, absence of distant metastases [M0]) were randomly assigned in a two-by-two factorial design to low or high dose 131-I (30 versus 100 mCi [1.1 versus 3.7 GBq]) and to ablation with thyroid hormone withdrawal versus administration of recombinant human thyrotropin (rhTSH) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/37\">",
"       37",
"      </a>",
"      ]. The rates of complete ablation at 6 to 10 months were similar (89.1 and 88.9 percent in patients receiving rhTSH and in those undergoing thyroid hormone withdrawal, respectively). The results did not change when the analysis was restricted to the 684 patients who received radioiodine and could be evaluated (91.7 and 92.9 percent, respectively). The efficacy was also equivalent with either dose. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Radioiodine dose (activity)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a similar multicenter trial, 438 patients with low-risk differentiated thyroid cancer (TNM stage T1 to T3 with possible lymph node involvement [N0, NX, N1] but no distant metastases [M0] and no microscopic residual disease) were randomly assigned to low or high dose radioiodine (30 versus 100 mCi [1.1 versus 3.7 GBq]) each combined with rhTSH or thyroid hormone withdrawal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/38\">",
"       38",
"      </a>",
"      ]. The rates of successful ablation were similar (87.2 and 86.8 percent for those who received rhTSH versus thyroid hormone withdrawal). The results did not change when the analysis was restricted to the 421 patients who received radioiodine and could be evaluated (87.1 versus 86.7 percent). The efficacy was also equivalent with either dose. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Radioiodine dose (activity)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No published study has yet evaluated the",
"    <strong>",
"     long-term",
"    </strong>",
"    outcomes of patients treated with adjuvant radioiodine with one preparative regimen compared with another. However, a retrospective study and a clinical trial found similar short-term recurrence rates in patients prepared with traditional thyroid hormone withdrawal compared to those prepared with rhTSH after a median follow-up of 2.5 to 3.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest rhTSH assisted RAI ablation in most thyroid cancer patients, reserving traditional thyroid hormone withdrawal for high-risk patients with known or suspected distant metastases or residual disease that is unlikely to respond well to RAI.",
"   </p>",
"   <p>",
"    Because of the lack of long-term data on recurrence and disease-specific survival from randomized trials, other centers are offering rhTSH ablation to only low-risk patients, preferring traditional hypothyroid withdrawal for patients at higher risk of recurrence or death from disease. But, for those patients in whom severe hypothyroidism might be relatively contraindicated (eg, the elderly, patients with depression, congestive heart failure, or severe sleep apnea), recombinant TSH may be administered to such patients, allowing them to remain on thyroid hormone therapy. This approach is consistent with the ATA guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/20\">",
"     20",
"    </a>",
"    ]. This topic is also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recombinant TSH is also used for stimulation of radioiodine uptake with diagnostic imaging. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Follow-up scanning and treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Low-iodine diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;To maximize uptake of RAI into thyroid cells, we suggest that patients follow a low-iodine diet for 7 to 10 days before and for one to two days after 131-I is administered (",
"    <a class=\"graphic graphic_table graphicRef75830 \" href=\"mobipreview.htm?42/1/43035\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. This suggestion is consistent with American Thyroid Association guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of eight observational studies, dietary iodine restriction (&lt;50 mcg daily) lasting anywhere from four days to four weeks prior to radioiodine administration compared with a normal diet reduced urinary iodine concentrations and increased 131-I uptake or lesional uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/44\">",
"     44",
"    </a>",
"    ]. In one retrospective study that assessed clinical outcomes, patients prescribed a low-iodine diet (24-hour urine iodine excretion 27 &plusmn; 12 mcg) compared with controls (24-hour urine excretion 159 &plusmn; 9 mcg) were more likely to have negative radioiodine uptake and thyroglobulin values &lt;2",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    when assessed six months after radioiodine treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/45\">",
"     45",
"    </a>",
"    ]. On the other hand, a subsequent retrospective study (not included in the meta-analysis) showed no relationship between urinary iodine excretion (range 25 to 1890",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    mean 132",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    and ablation success rates in a group of patients who were not routinely given a low iodine diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of a low-iodine diet before radioiodine treatment of metastatic nodal uptake is less well documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212897\">",
"    <span class=\"h3\">",
"     Recent iodine exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioiodine uptake by the thyroid remnant is reduced by the presence of excess circulating stable iodide. Thus, patients who have been exposed to high iodine loads (eg, iodinated contrast materials or medications high in iodine content, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) cannot have diagnostic radioiodine scans or receive radioiodine treatment until the iodine load is renally excreted. Twenty-four hour urinary iodine measurements can be used to document depletion of excess iodine loads in such patients. Once the 24-hour urine iodine content falls to about 100",
"    <span class=\"nowrap\">",
"     mcg/24",
"    </span>",
"    hours, patients can proceed with diagnostic RAI scans and RAI therapies. Many patients clear the iodine from iodinated contrast materials in three to six months, while the iodine load associated with amiodarone administration can persist for months to years after discontinuation of the drug. Plasma exchange has been used to decrease whole body iodine content in select patients that have persistent iodine contamination for months to years after discontinuation of amiodarone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients with distant metastases in whom the amiodarone cannot be discontinued should be treated as if they have RAI refractory metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'External beam radiotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Management of recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other strategies to increase uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other strategies can increase the efficiency of 131-I uptake by tumor, but at some risk. We suggest not using these strategies in the typical patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regimens to deplete body stores of iodine, such as the use of loop diuretics, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      with strict low iodine diets may increase uptake by tumor; however, there may also be a concomitant increase in total body irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      can prolong 131-I retention by thyroid tissue. In a small study of patients who had diagnostic 131-I scans before and then again after receiving lithium for one to two days, 131-I retention was higher and more prolonged during lithium administration in metastatic lesions and the thyroid remnants in most patients, so that the estimated 131-I dose to the metastases was higher [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/49\">",
"       49",
"      </a>",
"      ]. Whether these findings will result in improved eradication of metastases remains to be determined. The ATA guidelines state that the evidence is insufficient to recommend for or against lithium use in patients receiving 131-I [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"       Bexarotene",
"      </a>",
"      300 mg daily for six weeks has been reported to induce radioiodine uptake in non-iodine-avid thyroid cancer metastases; however, in one study, the increment in induced uptake was so small that there was no clinical benefit to subsequent radioiodine treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnostic scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic scans for localization of uptake before ablation or therapy are usually performed using low dose orally administered activities of 2 to 5 mCi (74 to 185 MBq) 131-I with whole body imaging 48 to 72 hours later to identify thyroid tissue and metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11\">",
"     11",
"    </a>",
"    ]. Alternatively, a 1.3 to 5 mCi (48 to 185 MBq) 123-I scan can be performed with whole body imaging 6 to 24 hours later. If present, the degree of uptake should be quantitated. Greater sensitivity for the detection of residual or metastatic tumor can be attained with the use of higher activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], but higher amounts (&gt;5 to 10 mCi 131-I) could lead to \"stunning,\" in which there is reduced uptake of the subsequent therapeutic radioiodine due to sublethal radiation delivered by the diagnostic dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Stunning may be the result of radiation-induced decrease in DNA synthesis as well as transcription of the sodium iodide symporter gene, as suggested by in vitro studies of porcine thyrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The importance of stunning may be overstated; one study found no difference in the success of subsequent treatment in patients who received 3 to 5 mCi (111 to 185 MBq) 131-I for scanning as compared with those not scanned before treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/57\">",
"     57",
"    </a>",
"    ]. A second study found no difference in the success rate of remnant ablation (negative iodine scan six to eight months later and undetectable thyroglobulin) when patients were scanned with 2mCi (74 MBq) of 131-I versus 0.5 mCi (14.8 MBq) 123-I before treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/58\">",
"     58",
"    </a>",
"    ]. The use of 123-I may be associated with a lower risk of stunning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/59\">",
"     59",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    Between one and seven days after administration of the diagnostic dose, whole body scans (WBS) are performed with a large field-of-view gamma-scintillation camera fitted with a high energy parallel hole collimator. Spot images of the neck and other areas of uptake can be obtained using either the same equipment or a rectilinear scanner. In some institutions, quantitative dosimetry is performed to determine lesion uptake and to predict effective tumor radiation dose; however, this requires specialized equipment and software [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between 75 and 100 percent of patients with thyroid cancer have 131-I uptake in the thyroid bed after thyroidectomy&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61870 \" href=\"mobipreview.htm?16/16/16640\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/60\">",
"     60",
"    </a>",
"    ]. Most often, this likely represents remnants of normal thyroid tissue rather than residual thyroid cancer. In contrast, only about 50 percent of metastatic lesions in the lungs or bones concentrate 131-I (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61482 \" href=\"mobipreview.htm?19/8/19599\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combining results from multiple studies, there is probably no significant difference between papillary and follicular carcinomas in the frequency of detectable uptake by recurrent or metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11\">",
"     11",
"    </a>",
"    ]. However, certain histologic subtypes, such as oxyphilic follicular cancer (commonly called H&uuml;rthle-cell cancer), the tall cell variant of papillary cancer, and poorly differentiated carcinomas, concentrate 131-I less often in metastatic sites. Older patients may also be less likely to have adequate uptake in metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/10,61\">",
"     10,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scans performed during follow-up that show apparent distant metastases must be interpreted with caution. A few are false-positive scans due to physiological uptake of the 131-I in the breast, salivary glands, or thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/62\">",
"     62",
"    </a>",
"    ]; false-positive scans can also occur with pathologic exudates, dilated hepatic ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/63\">",
"     63",
"    </a>",
"    ], or nonthyroid benign tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because almost all patients have thyroid remnants or metastases, another approach is to omit the pretreatment diagnostic scan, administer empiric therapeutic doses of 131-I therapy, and obtain only a post-treatment scan (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Post-treatment scanning'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/65\">",
"     65",
"    </a>",
"    ]. No studies have demonstrated superior outcomes following one or another approach. The disadvantage of omitting the diagnostic scan is that those patients with metastases may be under-treated by a strategy that gives all patients the same initial dose of radioiodine. Furthermore, there are occasional patients whose thyroidectomy is so complete that there is no uptake seen on the diagnostic scan and who, therefore, would not benefit from radioiodine therapy. In one study of 355 scans, the authors concluded that 53 percent of patients had findings on the pretreatment scan that might have altered management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/66\">",
"     66",
"    </a>",
"    ]. Omitting the diagnostic pretreatment scan may be reasonable for patients with a very low risk of metastases in whom the goal is to ablate remnants. The ATA guidelines recommend diagnostic scanning if the results of the scan would change the decision to treat with radioiodine or the administered activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When recombinant TSH is used to ablate remnants, the standard protocol is either (1) to obtain only a post-treatment scan or (2) to obtain a 24-hour 123-I scan on day three prior to administration of RAI ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     131I SPECT/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As one might expect, initial reports suggest an advantage of",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    scanning with radioiodine over traditional planar whole body scan imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. As an example, in one study of 81 inconclusive lesions on planar images, localization or characterization of the lesions was achieved by 83 to 85 percent of the 131I",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/67\">",
"     67",
"    </a>",
"    ]. In another study,",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    significantly altered the initial assessment of risk with a resultant impact on initial clinical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/69\">",
"     69",
"    </a>",
"    ]. This technology is not yet widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     123-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;123-I may be superior to 131-I for diagnostic scans. In one study of 14 patients following thyroidectomy, images obtained five hours after administration of 1.3 to 1.5 mCi (48 to 56 MBq) of 123-I detected more thyroid remnants than images obtained 48 hours after 3 mCi (111 MBq) of 131-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/70\">",
"     70",
"    </a>",
"    ]. Another study evaluated 12 patients, previously treated with radioiodine, who had high thyroglobulin concentrations and negative 131-I diagnostic scans. Eleven of the 12 patients had positive images 2 and 24 hours after administration of 5 mCi (185 MBq) 123-I; 10 of these 11 patients had concordant post-therapy (150 to 216 mCi [5.6 to 8.1 GBq]) 131-I scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/71\">",
"     71",
"    </a>",
"    ]. Since 123-I is primarily a gamma emitter, it does not impair cellular function and should not cause stunning, but it is considerably more expensive than 131-I.",
"   </p>",
"   <p>",
"    Because of the higher cost and shorter half-life of 123-I, most centers use 131-I (approximately 4 to 5 mCi) as the primary isotope for follow-up whole body scanning 6 to 12 months later. At our center, the initial diagnostic scan done prior to rhTSH ablation is done using 2 to 4 mCi of 123-I while all other routine follow up scans are done using 5 mCi of 131-I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radioiodine dose (activity)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Remnant ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;131-I is administered using a fixed-activity (fixed-dose) regimen, typically between 29 and 150 mCi (1.1 and 5.6 GBq) for remnant ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/4,72-74\">",
"     4,72-74",
"    </a>",
"    ]. In the past, patients given 30 mCi (1.1 GBq) or more had to be hospitalized, but that is no longer the case in the United States, except in the few states that have not changed their radiation protection rules. With the exception of patients presenting with distant metastases, whole body and blood dosimetry studies are rarely done as part of routine RAI ablation because the usual initial administered activities of 131-I are well below the expected maximal tolerable dose.",
"   </p>",
"   <p>",
"    Over the last few years, several international authorities on thyroid cancer have published guidelines recommending administered activities ranging from 30 to 150 mCi (1.1 to 5.6 GBq) of 131-I for remnant ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/75\">",
"     75",
"    </a>",
"    ]. Based upon concerns about dose-dependent complications after radioiodine therapy, the 2009 American Thyroid Association guidelines recommend using the minimal activity (30 to 100 mCi [1.1 to 3.7 GBq]) necessary to achieve successful ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/20\">",
"     20",
"    </a>",
"    ]. We choose the 131-I dose based upon the patient's prognosis. We suggest 30 to 50 mCi (1.1 to 1.8 GBq) for lower risk (such as patients under age 45 with tumors &lt;2 cm confined to the thyroid gland) and 75 to 100 mCi (2.8 to 3.7 GBq) 131-I for patients at intermediate risk, reserving doses of 150 to 200 mCi (5.6 to 7.4 GBq) for patients at high risk of local recurrence or death from macroscopic residual disease or distant metastases.",
"   </p>",
"   <p>",
"    Many studies have attempted to determine an optimal dose of RAI for ablation. In a 2007 systematic review of 41 retrospective studies, 12 prospective cohorts, and six randomized trials that compared low activity (about 30 mCi [1.1 GBq]) with higher activity (about 100 mCi [3.7 GBq]), the higher activities were associated with a slightly higher rate of successful ablation, but this did not reach statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/72\">",
"     72",
"    </a>",
"    ]. The analysis was confounded by differences in the definition of successful ablation used in the various studies, the non-randomized approach to dose selection in individual patients, the method of TSH stimulation, the adherence to a low iodine diet, and the length of time between ablation and the follow-up diagnostic scan. Thus, one could not reliably determine if there was a difference in the rates of successful ablation.",
"   </p>",
"   <p>",
"    In subsequent randomized trials designed to assess low versus high activity (30 or 50 versus 100 mCi [1.1 or 1.8 versus 3.7 GBq]) in patients with low-risk differentiated thyroid cancer, successful ablation rates at 6 to 10 months were similar (89 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/37,38,73\">",
"     37,38,73",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial, 752 patients with low-risk differentiated thyroid cancer (papillary or follicular, TNM stage T1 [&lt;1 cm] and N1 or NX, T1 &gt;1 to 2 cm with any N, or T2N0, absence of distant metastases [M0]) were randomly assigned in a two-by-two factorial design to low or high dose 131-I (30 versus 100 mCi [1.1 versus 3.7 GBq]) and to ablation with thyroid hormone withdrawal versus administration of recombinant human thyrotropin (rhTSH) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/37\">",
"       37",
"      </a>",
"      ]. Successful ablation was defined as a negative thyroid ultrasound (normal post-operative thyroid bed and no suspicious lymph nodes) and a rhTSH stimulated Tg &le;1",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      or in patients with detectable thyroglobulin antibodies, a negative 131-I total body scan (&lt;0.5 percent uptake in the thyroid bed). In the intention-to-treat analysis, complete ablation rates in the low and high-dose group were identical (89 percent). Similar compete ablation rates were found in an analysis limited to the 684 patients who received radioiodine and were evaluated 6 to 10 months later (91.1 and 93.5 percent for low and high-dose groups, respectively). The rates of complete ablation were also similar in patients receiving rhTSH versus thyroid hormone withdrawal (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Recombinant hTSH'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In another multicenter trial, 438 patients with low-risk differentiated thyroid cancer (TNM tumor stage T1 to T3, with possible lymph node involvement [N0, NX, N1] but no distant metastases [M0] and no microscopic residual disease) were randomly assigned to low or high dose radioiodine (30 versus 100 mCi [1.1 versus 3.7 GBq]), each combined with rhTSH or thyroid hormone withdrawal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/38\">",
"       38",
"      </a>",
"      ]. Successful ablation was defined as both a negative scan (&lt;0.1 percent uptake) and a rhTSH stimulated thyroglobulin level &lt;2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at six to nine months. Only the scan result was considered for ablation success or failure for patients with thyroglobulin antibodies and discordant thyroglobulin measurements on immunometric and radioimmunoassays, unknown antibody status, or unavailable serum sample. The rates of successful ablation were similar between the low and high dose groups (85 versus 88.9 percent). Success rates were also similar in those who received rhTSH versus thyroid hormone withdrawal (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Recombinant hTSH'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials that evaluate long-term outcomes of patients treated with low or high radioiodine dose (activity). In retrospective studies, there was no difference in thyroid cancer recurrence after five and 14.7 years of follow-up in patients treated with low versus high radioiodine activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, when a decision has been made to treat a patient with low-risk differentiated thyroid cancer with radioiodine for remnant ablation (",
"    <a class=\"graphic graphic_table graphicRef51570 \" href=\"mobipreview.htm?17/38/18029\">",
"     table 2",
"    </a>",
"    ), the available randomized trials support the recommendation to treat lower risk patients (such as patients under age 45 with tumors &lt;2 cm confined to the thyroid gland) with minimal activity (30 to 50 mCi [1.1 to 2.8 GBq]).",
"   </p>",
"   <p>",
"    The controversy about the role of 131-I remnant ablation in general, particularly in patients with low-risk disease (ie, no soft tissue invasion and no distant metastases), is reviewed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Treatment of residual thyroid tissue'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Residual or metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with residual postoperative disease in the thyroid bed or in local regional lymph nodes are usually treated with higher administered activities of 131-I. Efficacy has been reported with 150 mCi (5.550 GBq) as an average activity, either as a result of empiric therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/78\">",
"     78",
"    </a>",
"    ] or as determined by dosimetry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11\">",
"     11",
"    </a>",
"    ], wherein the maximum activity that will expose the bone marrow to &lt;200 rad can be calculated. Repeated dose of 131-I over several years has been shown to be highly effective in the treatment of younger patients with small volume pulmonary metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest 150 to 200 mCi (5.550 to 7.5 GBq) for most patients with pulmonary metastases and 200 mCi (5.550 to 7.5 GBq) for those with skeletal disease. However, empiric dosing regimens may exceed the maximum tolerable doses as predicted by dosimetry, especially in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. As an example, in one study, a dose of 200 mCi (7.5 GBq) exceeded the maximum tolerable dose in only 8 percent of younger patients and over 22 percent of patients over age 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/79\">",
"     79",
"    </a>",
"    ]. Therefore, doses should seldom exceed 150 mCi in patients 70 years or older unless guided by dosimetry studies. For patients with diffuse pulmonary metastases in whom pulmonary fibrosis could be a complication of radioiodine therapy, dosimetry can be used to limit the whole body radioiodine retention to 80 mCi at 48 hours, which will minimize pulmonary damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the same preparative regimen described above for ablation, we suggest the following activities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      150 mCi (5.550 GBq) 131-I to treat uptake in lymph nodes in the neck and mediastinum.",
"     </li>",
"     <li>",
"      150 to 200 mCi dose (5.550 to 7.5 GBq) for patients with pulmonary metastases.",
"     </li>",
"     <li>",
"      200 mCi (7.5 GBq) for patients with skeletal or other distant metastatic disease.",
"     </li>",
"     <li>",
"      Higher activities may be given to patients who have recurrent disease after previous therapy, but should be based on dosimetry to ascertain their safety.",
"     </li>",
"     <li>",
"      In patients with renal failure or on hemodialysis, there are two dosing approaches to radioiodine therapy: a substantially lower dose of radioiodine followed by the patient's usual dialysis schedule, or a standard radioiodine dose followed by more frequent dialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/82,83\">",
"       82,83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Post-treatment scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor uptake of the treatment dose of 131-I should be confirmed by performing a whole body scan two to eight days after treatment. In about 20 percent of these posttreatment scans, foci of uptake that were not seen on the corresponding low-dose 131-I diagnostic scan are seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. However, in only 10 percent of cases does the posttreatment scan reveal new sites of uptake that significantly alter the patient's prognosis and were not known to exist by other means, such as radiography or surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, in a comparison of diagnostic 123-I scans with posttreatment scans, additional areas of uptake were found in 6 percent of patients scanned for the first time, 18 percent of patients scanned for the second time, and 44 percent of patients with high serum thyroglobulin concentrations and negative diagnostic scans; however, treatment was altered in few patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/84\">",
"     84",
"    </a>",
"    ]. The clinical utility of these scans is lowest in older patients receiving their first 131-I treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/54\">",
"     54",
"    </a>",
"    ]; however, the information obtained on the post-therapy scan can guide follow-up recommendations and should be done routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Follow-up scanning and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We usually repeat the radioiodine diagnostic scan with 123-I or 131-I 6 to 12 months after treatment with 131-I in moderate to high-risk patients and in lower risk patients who have detectable thyroglobulin levels during follow-up that are not declining. If significant uptake is seen within the thyroid bed (&gt;1 percent), one more treatment with 100 to 150 mCi (3.7 to 5.550 GBq) of 131-I may be given to complete the ablation; generally, we are reluctant to repeat treatment of minor thyroid bed uptake (&lt;1 percent) in the absence of clear evidence of residual cancer by other imaging techniques such as ultrasound.",
"   </p>",
"   <p>",
"    If there is uptake outside of the thyroid bed, we give doses of 131-I appropriate to the site of uptake. Prior to incorporating stimulated thyroglobulin testing into diagnostic algorithms, a common approach was to continue scanning to obtain two successive negative 131-I scans, which predicted a 97 percent 10-year relapse-free survival compared with 91 percent after only one negative scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the advent of stimulated thyroglobulin testing either by hormone withdrawal or thyrotropin alpha, a single negative",
"    <span class=\"nowrap\">",
"     scan/thyroglobulin",
"    </span>",
"    combination may be sufficient in Stage III or IV patients, and lower risk patients with negative thyroglobulin levels may not require follow-up scanning at all. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37496?source=see_link\">",
"     \"Serum thyroglobulin in the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For each scan, the patient's serum TSH concentration must be high enough to maximize the uptake of 131-I by any residual thyroid tissue. This may be achieved with thyroid hormone withdrawal or by administration of recombinant human TSH (rhTSH, thyrotropin alfa).",
"   </p>",
"   <p>",
"    We suggest using rhTSH support in all patients who require radioiodine scanning, unless they are thought to be likely in need of subsequent radioiodine therapy that is preferably done using thyroid hormone withdrawal. Imaging is usually done at 48 hours using the rhTSH approach, or at 48 to 72 hours following thyroid hormone withdrawal. The use of rhTSH before radioiodine imaging is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone withdrawal versus recombinant human TSH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic complications of 131-I can limit the usefulness of this treatment. In the short term, radiation thyroiditis, painless neck edema, sialadenitis, and tumor hemorrhage or edema occur in 10 to 30 percent of patients, particularly when higher doses are given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11,86\">",
"     11,86",
"    </a>",
"    ]. Nausea after 131-I administration can be treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , 10 mg. To promote more rapid clearance of radioiodine from the urinary bladder, patients are encouraged to drink large volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laxatives that do not contain iodine should be given if the patient has not had a bowel movement within 12 to 24 hours after administration of the RAI (to purge radioiodine from the colon).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Sialadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients treated with 131-I experience dose-related reductions in salivary flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/88\">",
"     88",
"    </a>",
"    ], and some experience transient decreased or altered sense of taste. Although previously thought to reduce the risk of sialadenitis, the use of lemon candies in the first 24 hours was associated with higher rates of sialoadenitis, hypogeusia, and xerostomia due to increased hematogenous delivery of radioiodine to salivary gland tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Therefore, the use of lemon candies or other sialogogues as a means to reduce radiation sialadenitis remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Since radioiodine is washed out rapidly after the administration of lemon juice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/91\">",
"     91",
"    </a>",
"    ], additional studies are needed to determine optimal timing of administration to reduce delivery of radioiodine to the salivary glands and provide optimal washout.",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs are usually adequate for relieving symptoms of acute sialadenitis; glucocorticoids are rarely required but are effective in more severe cases. In a related observation, dental caries and teeth extraction were markedly higher in patients who developed postradioiodine xerostomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/92\">",
"     92",
"    </a>",
"    ], and patients should be advised about proper oral hygiene and regular dental care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822348#H3822348\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Salivary gland damage and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    , which functions as a radioprotectant by scavenging radiation-induced free radicals in non-malignant tissue, has been advocated to reduce the frequency and severity of sialadenitis after radioiodine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. But, it is possible that amifostine would protect normal thyroid tissue from radiation-induced damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/95\">",
"     95",
"    </a>",
"    ], and therefore its use should probably be limited to the occasional patient who requires multiple radioiodine administrations for metastatic disease rather than for adjuvant remnant ablation. Fewer side effects have been reported with subcutaneous administration, 500 mg, before radioiodine ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Secondary malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An excess risk of secondary malignancies has been reported after radioiodine therapy for thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/86,96\">",
"     86,96",
"    </a>",
"    ]. Given the presence of sodium iodide symporters in salivary glands and estrogenized breast tissue, and the gastrointestinal and urinary routes of excretion of radioiodine, salivary gland, breast, bladder, and gastrointestinal cancers can be plausibly hypothesized to occur more frequently in thyroid cancer patients treated with radioiodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/97-102\">",
"     97-102",
"    </a>",
"    ]. The risk of acute myeloid leukemia is also increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11,97,103\">",
"     11,97,103",
"    </a>",
"    ]. The reported prevalence is approximately 0.5 percent, usually occurring between 2 and 10 years after I-131 therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk is considerably lower when the total blood dose per treatment is less than 2 to 3 Gy and multiple smaller treatments are given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11,97\">",
"     11,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 6840 patients treated for thyroid cancer in Sweden, Italy, and France, 62 percent received radioiodine therapy (mean cumulative activity 162 mCi [6.0 GBq]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/104\">",
"     104",
"    </a>",
"    ]. Secondary malignancies that occurred with significantly increased risk included bone and soft tissue (relative risk [RR] 4.0), female genital organs (RR 2.2), central nervous system (RR 2.2), and leukemia (RR 2.5). A dose-response relationship was seen between the administered activity and the risk for solid malignancies as well as leukemia. Although breast cancer was more commonly diagnosed in women treated for thyroid cancer, no relationship was identified between radioiodine and breast disease.",
"   </p>",
"   <p>",
"    The National Cancer Institute's Surveillance, Epidemiology, and End Results program (SEER) found that the absolute excess risk was 6.39 cases of secondary malignancies per 10,000 person-years in an analysis of 30,278 patients followed for up to 30 years (mean 103 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of the above two studies found a relative risk of secondary malignancies of 1.19 in thyroid cancer patients given radioiodine compared with those not treated with radioiodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an analysis of patients in the SEER database who had low-risk (T1N0) well differentiated thyroid cancer, the excess absolute risk was 4.6 cases of secondary malignancies per 10,000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/107\">",
"     107",
"    </a>",
"    ]. Secondary malignancies with significantly elevated risk due to radioiodine were salivary gland malignancies and leukemia (standardized incidence ratios 11.13 and 5.68, respectively). During the 35-year study period, the rate of radioiodine use in patients with low-risk well differentiated thyroid cancer increased from 3.3 to 38.1 percent.",
"   </p>",
"   <p>",
"    It is important to note that while high cumulative doses of RAI may be associated with a statistically significant increase in second malignancies (relative risk), the magnitude of this risk (absolute risk) is quite small. However, any risk of secondary malignancy requires a careful analysis of the risk versus benefit of RAI for patients with low-risk disease and additional RAI therapies in patients with persistent or recurrent thyroid cancer.",
"   </p>",
"   <p>",
"    Also of note is the lower total body radiation exposure in patients prepared with rhTSH versus thyroid hormone withdrawal due to the more rapid clearance of radioiodine from euthyroid versus hypothyroid patients. In one study, the frequency of translocations in peripheral lymphocytes after radioiodine was higher in patients prepared by withdrawal compared to those prepared with rhTSH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Gonadal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient oligospermia and decreases in ovarian function may occur, but subsequent male infertility is rare except after high doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of men receiving less than 150 mCi (5.5 GBq) of radioiodine, there was a transient rise in FSH, but no oligospermia or change in serum testosterone levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/110\">",
"       110",
"      </a>",
"      ]; one-third of men who received 350 to 750 mCi (13 to 27.7 GBq) developed transient oligospermia. A systematic review concluded that biochemical evidence of gonadal damage can be seen for up to 18 months after radioiodine treatment, but effects on fertility and offspring were not identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient amenorrhea for one to four months occurs in roughly 10 to 25 percent of women treated with radioiodine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/113\">",
"       113",
"      </a>",
"      ]. In a study of women who had received 131-I therapy for thyroid cancer before age 45 years, menopause occurred on average 1.5 years earlier than in women with nodular goiter treated with equivalent doses of T4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic and chromosomal abnormalities in children due to parental exposure to 131-I probably occurs in only 1 percent of live births after cumulative administered doses of 500 mCi (18.500 GBq), and even less frequently after lower doses. The outcome of pregnancy in women treated with 131-I before becoming pregnant is usually normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/113-116\">",
"       113-116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nasolacrimal duct obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct obstruction, presenting as epiphora (excessive tearing), has been reported to occur after as low an administered activity as 100 mCi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/117\">",
"     117",
"    </a>",
"    ] and can be a cause of a false-positive radioiodine scan in the orbit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130958617\">",
"    <span class=\"h1\">",
"     RADIATION SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the American Thyroid Association (ATA) published recommendations on radiation safety for patients, families, caregivers, and the public after radioiodine (131-I) therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/21\">",
"     21",
"    </a>",
"    ]. The recommendations are based upon clinical experience and available data. However, data on long-term outcomes are limited. The recommendations are in keeping with Nuclear Regulatory Commission (NRC) regulations and the principle of reducing radiation exposure to levels that are as low as reasonably achievable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130958638\">",
"    <span class=\"h2\">",
"     Patient release criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to NRC regulations, a patient treated with 131-I may be released from the care of the treating clinician as long as the radiation exposure to another individual caring for the patient will not exceed 5 milliSieverts (mSv, 500 mrem) per year and the exposure to the public, a child, or a pregnant woman will not exceed 1 mSv (100 mrem) in one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. Radiation exposure can be calculated in mrem or mSv using dose rate meters or a total dose effective equivalent (TEDE) table. The calculation of the total dose effective equivalent takes into account patient-specific information, such as the administered 131-I activity, the physical and biological half-life of the 131-I, and the projected duration of exposure time for family members or caregivers. Dose rates are established for a distance of 1 m (approximately three feet) from the radiation source (ie, the patient). Patients receiving a dose of 150 mCi (5550 MBq) for thyroid cancer can typically be released without exceeding dose limits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/21,121\">",
"     21,121",
"    </a>",
"    ]. When the total dose effective equivalent exceeds NRC regulations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when patients are unable to comply with post treatment precautions, inpatient 131-I dosing is necessary. A Radiation Safety Officer will generally oversee radiation safety calculations and precautions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192459836\">",
"    <span class=\"h2\">",
"     Post-treatment precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who receive radioiodine have the potential to expose their home and household contacts to very low levels of radiation via saliva, urine, or radiation emitting from their body. To ensure the safety of family members, caregivers, and other individuals, several precautions are recommended. We agree with ATA guidelines as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192459850\">",
"    <span class=\"h3\">",
"     Safety for the general public and household members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treated patients should be given patient-specific advice on the necessary precautions to reduce radiation exposure (",
"    <a class=\"graphic graphic_table graphicRef53135 \" href=\"mobipreview.htm?34/61/35806\">",
"     table 4",
"    </a>",
"    ). The treated patient should remain &ge;1.8 m (six feet) away from family members, caregivers, and the general public as much as possible for approximately 24 hours after treatment. Adult caregivers may be closer than 1 m (three feet) for brief intervals. In general, the treated patient should be instructed to avoid public transportation and extended time in public places, and should not stay overnight in a hotel or motel within 24 hours of 131-I treatment.",
"   </p>",
"   <p>",
"    To protect household members from radiation exposure, the treated patient should avoid the following during the restricted period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleeping in the same bed with another adult, pregnant woman, infant, or child",
"     </li>",
"     <li>",
"      Sexual contact",
"     </li>",
"     <li>",
"      Kissing",
"     </li>",
"     <li>",
"      Sharing cups, utensils, towels, razors, toothbrushes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of the restricted period depends upon the dose received, amount of thyroid tissue, and rate of clearance. As an example, treated patients should avoid sleeping in the same bed with an adult for four days and for up to three weeks with a pregnant partner, infant, or child after treatment with 200 mCi (7400 MBq). The restricted period is calculated individually for each treated patient (",
"    <a class=\"graphic graphic_table graphicRef74127 \" href=\"mobipreview.htm?22/24/22925\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are few long-term data to assess the protective benefits of these precautions. In a study of 30 patients with thyroid cancer who received 75 to 150 mCi (2.775 to 5.550 GBq) of 131-I as outpatients, exposure of family members was minimal when precautions were followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/122\">",
"     122",
"    </a>",
"    ]. Patients were instructed to sleep alone, drink fluids liberally, and avoid prolonged close personal contact with family members for two days after treatment. Surveillance of family members and pets demonstrated that doses to household members were well below the limit (5.0 mSv) mandated by NRC regulations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192459857\">",
"    <span class=\"h3\">",
"     Personal hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;131-I is renally excreted, and excretion is maximal during the first 48 hours after treatment. Patients should stay well-hydrated (3 to 4 L of fluid daily) and void frequently. To avoid personal or caregiver contamination, patients should be meticulous in their personal hygiene, wiping any surfaces that may become contaminated with urine, stool, vomitus, blood, or perspiration for 48 hours after treatment (",
"    <a class=\"graphic graphic_table graphicRef53135 \" href=\"mobipreview.htm?34/61/35806\">",
"     table 4",
"    </a>",
"    ). For 48 hours after therapy, men should sit when urinating. Exercise equipment should be wiped with flushable or disposable wipes. Exercise and bed clothes can be laundered in a washing machine. Dishes and utensils can be washed by hand or in a dishwasher. Flushable waste can be flushed down the toilet. Non-flushable waste (ie, incontinence pads) should be disposed of in a plastic trash bag devoted to radiation waste. Caregivers should wear disposable plastic gloves during clean-up. Radiation waste bags can be returned to the nuclear medicine facility one to two weeks after treatment, or stored in the household (six feet away from people or animals) for 80 days. After 80 days, radiation related trash can be disposed of with regular household trash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192459865\">",
"    <span class=\"h3\">",
"     International travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of 131-I activity (0.0003 mCi [0.01 MBq]) can be picked up by radiation detection systems at airports or international borders. Treated patients may trigger alarms for as long as 95 days post-therapy. Thus, patients who are travelling within three to four months of receiving 131-I require documentation specifying the date of treatment, type and dose of radionuclide, the treating facility, and contact information for the treating clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2003100\">",
"    <span class=\"h3\">",
"     Future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In female thyroid cancer patients, pregnancy should generally be delayed for at least six months after radioiodine therapy to ensure that additional diagnostic imaging or additional radiation treatment is not required. In men, it seems reasonable to delay attempts to produce pregnancy for a period of three to four months to allow recovery of the transient oligospermia that may follow RAI therapy. However, in some men, full fertility may not be restored until one year or more after treatment, especially in men receiving high cumulative doses of radioiodine (&gt;350 mCi) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/13/34010/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for I-131 administration in the post-thyroidectomy treatment of patients with differentiated thyroid cancer include ablation of residual thyroid tissue, imaging for possible metastatic disease, and treatment of possible or known residual or metastatic thyroid cancer.",
"   </p>",
"   <p>",
"    Available data suggest improved overall survival with postsurgical radioiodine (RAI) treatment in many higher risk patients. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Treatment of residual thyroid tissue'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our approach to the use of radioiodine ablation is consistent with the 2009 ATA guidelines, which are based upon the clinico-pathologic features of each case, rather than a specific staging system (",
"    <a class=\"graphic graphic_table graphicRef51570 \" href=\"mobipreview.htm?17/38/18029\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We currently recommend postoperative radioiodine ablation for all patients with known distant metastases, gross extrathyroidal extension of the tumor regardless of tumor size, or primary tumor &gt;4 cm even in the absence of other high-risk features (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest radioiodine ablation for select patients with tumor size 1 to 4 cm confined to the thyroid, who have documented lymph node metastases or other high-risk features (eg, vascular invasion, more aggressive histologic subtypes, such as tall cell, columnar cell, insular, or poorly differentiated histologies) when the combination of age, tumor size, lymph node status, and individual histology predicts an intermediate to high risk of recurrence or death from thyroid cancer (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of a proven benefit on either disease-free survival or recurrence, we suggest",
"      <strong>",
"       against",
"      </strong>",
"      radioiodine ablation for patients with unifocal tumors &lt;1 cm without other high-risk features or for patients with multifocal cancer when all foci are &lt;1 cm in the absence of other high-risk features, even in the presence of small volume regional lymph node metastases (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for radioiodine dose (activity) are reviewed above. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Radioiodine dose (activity)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prepare for radioiodine remnant ablation or diagnostic testing (imaging), we suggest recombinant human TSH (rhTSH) for most patients to raise serum TSH levels for adequate radioiodine uptake (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recombinant hTSH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients follow a low-iodine diet for 7 to 10 days before radioiodine is given for remnant ablation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      To protect household members from radiation exposure, the treated patient should avoid: sleeping in the same bed with another adult, pregnant woman, infant, or child; sexual contact; kissing; and sharing cups, utensils, towels, razors, and toothbrushes during the restricted period (",
"      <a class=\"graphic graphic_table graphicRef74127 \" href=\"mobipreview.htm?22/24/22925\">",
"       table 5",
"      </a>",
"      ). The duration of the restricted period depends upon the dose received, amount of thyroid tissue, and rate of clearance. (See",
"      <a class=\"local\" href=\"#H130958617\">",
"       'Radiation Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/1\">",
"      Spitzweg C, Harrington KJ, Pinke LA, et al. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001; 86:3327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/2\">",
"      Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 1990; 19:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/3\">",
"      DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/4\">",
"      Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/5\">",
"      Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/6\">",
"      Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/7\">",
"      Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/8\">",
"      Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010; 20:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/9\">",
"      Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/10\">",
"      Maxon, HRd, Englaro, EE, Thomas, SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients [see comments]. J Nucl Med 1992; 33:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/11\">",
"      Maxon, HR, Smith, HS. Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/12\">",
"      Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 1996; 78:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/13\">",
"      Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/14\">",
"      Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/15\">",
"      Sisson JC, Jamadar DA, Kazerooni EA, et al. Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid 1998; 8:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/16\">",
"      Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997; 82:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/17\">",
"      Sabra M, Grewal R, Tala H, et al. Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell Derived Thyroid Carcinoma with Negative Diagnostic but Positive Post-therapy 131-I Whole Body Scans. Thyroid 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/18\">",
"      Wang W, Larson SM, Tuttle RM, et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 11:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/19\">",
"      Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/20\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/21\">",
"      American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid 2011; 21:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/22\">",
"      Brzozowska M, Roach PJ. Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer: a case series. Clin Nucl Med 2006; 31:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/23\">",
"      Tuttle RM, Lopez N, Leboeuf R, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 2010; 20:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/24\">",
"      Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab 2011; 96:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/25\">",
"      Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients. Clin Endocrinol (Oxf) 2002; 57:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/26\">",
"      Serhal DI, Nasrallah MP, Arafah BM. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/27\">",
"      Goldman JM, Line BR, Aamodt RL, Robbins J. Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980; 50:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/28\">",
"      Leboeuf R, Perron P, Carpentier AC, et al. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf) 2007; 67:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/29\">",
"      Guimaraes V, DeGroot LJ. Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid 1996; 6:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/30\">",
"      Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88:4110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/31\">",
"      Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002; 43:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/32\">",
"      Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/33\">",
"      Chianelli M, Todino V, Graziano FM, et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009; 160:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/34\">",
"      Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010; 20:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/35\">",
"      Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/36\">",
"      Ma C, Xie J, Liu W, et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database Syst Rev 2010; :CD008302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/37\">",
"      Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/38\">",
"      Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/39\">",
"      Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008; 49:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/40\">",
"      Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009; 94:4171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/41\">",
"      Park JT 2nd, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine. Thyroid 2004; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/42\">",
"      Maxon HR, Thomas SR, Boehringer A, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 1983; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/43\">",
"      Maruca J, Santner S, Miller K, Santen RJ. Prolonged iodine clearance with a depletion regimen for thyroid carcinoma: concise communication. J Nucl Med 1984; 25:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/44\">",
"      Sawka AM, Ibrahim-Zada I, Galacgac P, et al. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid 2010; 20:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/45\">",
"      Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2003; 58:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/46\">",
"      Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 2010; 95:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/47\">",
"      Toubert ME, Dib-Deperrest A, Houz&eacute; P, et al. Plasma exchanges overcome persistent iodine overload to enable 131I ablation of differentiated thyroid carcinoma. Thyroid 2008; 18:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/48\">",
"      Matovic MD, Jankovic SM, Jeremic M, et al. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131. Thyroid 2009; 19:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/49\">",
"      Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/50\">",
"      Liu YY, Stokkel MP, Morreau HA, et al. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 68:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/51\">",
"      Nmec J, R&ouml;hling S, Zamrazil V, Pohunkov&aacute; D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979; 20:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/52\">",
"      Waxman A, Ramanna L, Chapman N, et al. The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981; 22:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/53\">",
"      Park HM. Stunned thyroid after high-dose I-131 imaging. Clin Nucl Med 1992; 17:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/54\">",
"      Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/55\">",
"      Lundh C, Nord&eacute;n MM, Nilsson M, Forssell-Aronsson E. Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med 2007; 48:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/56\">",
"      Nord&eacute;n MM, Larsson F, Tedelind S, et al. Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res 2007; 67:7512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/57\">",
"      Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/58\">",
"      Silberstein EB. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 2007; 48:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/59\">",
"      Hilditch TE, Dempsey MF, Bolster AA, et al. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging 2002; 29:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/60\">",
"      Salvatori M, Raffaelli M, Castaldi P, et al. Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma. Eur J Surg Oncol 2007; 33:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/61\">",
"      Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/62\">",
"      Wilson LM, Barrington SF, Morrison ID, et al. Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med 1998; 25:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/63\">",
"      You DL, Tzen KY, Chen JF, et al. False-positive whole-body iodine-131 scan due to intrahepatic duct dilatation. J Nucl Med 1997; 38:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/64\">",
"      Rudoni S, Toubeau M, Mansuy S, et al. [False positive scintigraphic images in the surveillance of differentiated thyroid cancers]. Ann Endocrinol (Paris) 1997; 58:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/65\">",
"      Salvatori M, Perotti G, Rufini V, et al. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan? Clin Endocrinol (Oxf) 2004; 61:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/66\">",
"      Van Nostrand D, Aiken M, Atkins F, et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid 2009; 19:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/67\">",
"      Chen L, Luo Q, Shen Y, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med 2008; 49:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/68\">",
"      Wong KK, Zarzhevsky N, Cahill JM, et al. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol 2008; 191:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/69\">",
"      Grewal RK, Tuttle RM, Fox J, et al. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med 2010; 51:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/70\">",
"      Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/71\">",
"      Siddiqi A, Foley RR, Britton KE, et al. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol (Oxf) 2001; 55:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/72\">",
"      Hackshaw A, Harmer C, Mallick U, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007; 92:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/73\">",
"      Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/74\">",
"      Ros&aacute;rio PW, Borges MA, Valad&atilde;o MM, et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid 2007; 17:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/75\">",
"      Tuttle RM, Leboeuf R, Martorella AJ. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 2007; 36:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/76\">",
"      Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/77\">",
"      Ros&aacute;rio PW, Purisch S, Vasconcelos FP, et al. Long-term recurrence of thyroid cancer after thyroid remnant ablation with 1.1 and 3.7 GBq radioiodine. Nucl Med Commun 2007; 28:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/78\">",
"      Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/79\">",
"      Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006; 47:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/80\">",
"      Kulkarni K, Van Nostrand D, Atkins F, et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 2006; 16:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/81\">",
"      BENUA RS, CICALE NR, SONENBERG M, RAWSON RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/82\">",
"      Holst JP, Burman KD, Atkins F, et al. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid 2005; 15:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/83\">",
"      Murcutt G, Edwards J, Boakye J, Davenport A. Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy. Kidney Int 2008; 73:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/84\">",
"      Alzahrani AS, Bakheet S, Al Mandil M, et al. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning. J Clin Endocrinol Metab 2001; 86:5294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/85\">",
"      Grigsby PW, Baglan K, Siegel BA. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 1999; 85:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/86\">",
"      Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw 2010; 8:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/87\">",
"      Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/88\">",
"      Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 1996; 35:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/89\">",
"      Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/90\">",
"      Jentzen W, Balschuweit D, Schmitz J, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 2010; 37:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/91\">",
"      Van Nostrand D, Bandaru V, Chennupati S, et al. Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice. Thyroid 2010; 20:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/92\">",
"      Walter MA, Turtschi CP, Schindler C, et al. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med 2007; 48:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/93\">",
"      Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. Cancer Biother Radiopharm 1999; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/94\">",
"      Mendoza A, Shaffer B, Karakla D, et al. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid 2004; 14:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/95\">",
"      Zoberi I, Wasserman TH, Chao KS. A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers. Semin Radiat Oncol 2002; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/96\">",
"      Lang BH, Wong IO, Wong KP, et al. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery 2012; 151:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/97\">",
"      Glanzmann C. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther Onkol 1992; 168:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/98\">",
"      Chen AY, Levy L, Goepfert H, et al. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001; 92:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/99\">",
"      Li CI, Rossing MA, Voigt LF, Daling JR. Multiple primary breast and thyroid cancers: role of age at diagnosis and cancer treatments (United States). Cancer Causes Control 2000; 11:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/100\">",
"      Adjadj E, Rubino C, Shamsaldim A, et al. The risk of multiple primary breast and thyroid carcinomas. Cancer 2003; 98:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/101\">",
"      Hall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 64:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/102\">",
"      de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997; 75:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/103\">",
"      Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/104\">",
"      Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/105\">",
"      Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/106\">",
"      Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009; 19:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/107\">",
"      Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 117:4439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/108\">",
"      Frigo A, Dardano A, Danese E, et al. Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab 2009; 94:3472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/109\">",
"      Hyer S, Vini L, O'Connell M, et al. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 2002; 56:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/110\">",
"      Ros&aacute;rio PW, Barroso AL, Rezende LL, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. Thyroid 2006; 16:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/111\">",
"      Ceccarelli C, Bencivelli W, Morciano D, et al. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001; 86:3512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/112\">",
"      Sawka AM, Lea J, Alshehri B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) 2008; 68:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/113\">",
"      Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 2008; 69:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/114\">",
"      Lin JD, Wang HS, Weng HF, Kao PF. Outcome of pregnancy after radioactive iodine treatment for well differentiated thyroid carcinomas. J Endocrinol Invest 1998; 21:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/115\">",
"      Bal C, Kumar A, Tripathi M, et al. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. Int J Radiat Oncol Biol Phys 2005; 63:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/116\">",
"      Garsi, JP, Schlumberger, M, Rubino, C et al. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies, J Nucl Med 2008; 49:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/117\">",
"      Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002; 87:5817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/118\">",
"      Shepler TR, Sherman SI, Faustina MM, et al. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg 2003; 19:479.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/sr1556v9r2-final.pdf#08-33 (Accessed on April 22, 2011).",
"    </li>",
"    <li>",
"     file://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/sr1556v9r2-final.pdf#08-36 (Accessed on April 22, 2011).",
"    </li>",
"    <li>",
"     United States Nuclear Regulatory Commission (NRC). Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Medical Use Licenses, 2008. file://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/sr1556v9r2-final.pdf#08-36 (Accessed on May 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/13/34010/abstract/122\">",
"      Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. JAMA 2000; 283:2272.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7818 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34010=[""].join("\n");
var outline_f33_13_34010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment of residual thyroid tissue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Residual tumor and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Residual tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192459723\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Thyroid hormone withdrawal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recombinant hTSH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Low-iodine diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1212897\">",
"      - Recent iodine exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other strategies to increase uptake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnostic scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - 131I SPECT/CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - 123-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radioiodine dose (activity)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Remnant ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Residual or metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Post-treatment scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Follow-up scanning and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Secondary malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Gonadal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nasolacrimal duct obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130958617\">",
"      RADIATION SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130958638\">",
"      Patient release criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192459836\">",
"      Post-treatment precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192459850\">",
"      - Safety for the general public and household members",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192459857\">",
"      - Personal hygiene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192459865\">",
"      - International travel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2003100\">",
"      - Future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7818|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/16/16640\" title=\"diagnostic image 1\">",
"      131 I scan in thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/8/19599\" title=\"diagnostic image 2\">",
"      Scan metastatic thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7818|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/45/44766\" title=\"figure 1\">",
"      RAI in thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7818|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/51/35644\" title=\"table 1\">",
"      NTCTCSG staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/38/18029\" title=\"table 2\">",
"      Factors RAI ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/1/43035\" title=\"table 3\">",
"      Iodine containing foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/61/35806\" title=\"table 4\">",
"      Safety instructions for patients receiving radioiodine treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/24/22925\" title=\"table 5\">",
"      Precaution requirements after treatments with 131-I carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/16/14599?source=related_link\">",
"      Clinicopathologic staging of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37496?source=related_link\">",
"      Serum thyroglobulin in the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_13_34011="Transgenic obese mice";
var content_f33_13_34011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Transgenic animals with altered body fat",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased body fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knockout of melanocortin-4 receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduction in brain glucocorticoid receptor by antisense mRNA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overexpression of corticotropin-releasing hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knockout of uncoupling protein in brown adipose tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overexpression of agouti protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knockout of beta-3 adrenergic receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overexpression of GLUT-4 in fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracellular adhesion molecule-1 knockout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased body fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knockout of the GLUT-4 gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overexpression of lipoprotein lipase in muscle and cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overexpression of uncoupling protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overexpression of glycerol 3-dehydrogenase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knockout of protein kinase A (RIIb)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin 2C receptor knockout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overexpression of glucokinase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knockout of the eIF4E-BP1 gene",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34011=[""].join("\n");
var outline_f33_13_34011=null;
var title_f33_13_34012="Exercise prescription";
var content_f33_13_34012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Exercise prescription for endurance and resistance training for cardiovascular fitness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Endurance training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        3 to 5 days/wk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Intensity",
"       </td>",
"       <td>",
"        55 to 90 percent maximum HR OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 85 percent maximum VO2 OR HRR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration",
"       </td>",
"       <td>",
"        20 to 60 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Modality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"3\">",
"        Lower extremity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Walking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Jogging/running",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Stairclimber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Upper extremity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Arm ergometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"5\">",
"        Combined",
"       </td>",
"       <td class=\"sublist_other\">",
"        Rowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Cross-country ski machine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Combined arm/leg cycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Swimming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Aerobics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Resistance training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        2 to 3 days/wk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intensity",
"       </td>",
"       <td>",
"        1 to 3 sets of 8 to 15 RM for each muscle group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Modality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"2\">",
"        Lower extremity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Leg extensions, curls, presses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Adductors/abductors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"5\">",
"        Upper extremity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Biceps curls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Triceps extensions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Bench/overhead presses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Lateral pulldowns/raises",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Benchovers/seated rowing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Modalities listed here are not all-inclusive.",
"    <br>",
"     Maximum heart rate (HR) indicates 220 minus age or peak HR on exercise test.",
"     <br>",
"      Heart rate reserve (HRR) = (Peak HR - Resting HR); goal intensity is 40 to 85 percent of the HRR added to the resting HR.",
"      <div class=\"footnotes\">",
"       VO2: measured oxygen intake; RM: maximum number of times a load can be lifted before fatigue.",
"      </div>",
"      <div class=\"reference\">",
"       Data from: Shepard RJ, Balady GJ. Circulation 1999; 99:963.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34012=[""].join("\n");
var outline_f33_13_34012=null;
var title_f33_13_34013="Cerebral autoregulation in hypertension";
var content_f33_13_34013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cerebral autoregulation in hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of autoregulation of cerebral blood flow in normotensive and hypertensive subjects. In both groups, initial increases or decreases in mean arterial pressure are associated with maintenance of cerebral blood flow due to appropriate changes in arteriolar resistance. More marked changes in pressure are eventually associated with loss of autoregulation, leading to a reduction (with hypotension) or an elevation (with marked hypertension) in cerebral blood flow. These changes occur at higher pressures in patients with hypertension, presumably due to arteriolar thickening. Thus, aggressive antihypertensive therapy will produce cerebral ischemia at a higher mean arterial pressure in patients with underlying hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kaplan, NM, Lancet 1994; 344:1335.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34013=[""].join("\n");
var outline_f33_13_34013=null;
var title_f33_13_34014="Axillary artery puncture";
var content_f33_13_34014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axillary artery puncture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Technique of axillary artery puncture. The arm should be hyperabducted and externally rotated. The needle should be inserted into the artery as high as possible within the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34014=[""].join("\n");
var outline_f33_13_34014=null;
var title_f33_13_34015="Intense corneal inflammation RA";
var content_f33_13_34015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intense corneal inflammation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe intrastromal corneal inflammation in a patient with rheumatoid arthritis for many years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_13_34015=[""].join("\n");
var outline_f33_13_34015=null;
